| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Leucovorin**<br>50 mg/5 mL<br>200 mg/20 mL<br>1000 mg/100 mL<br>(GMP)<br>(F)(PFL)<br>no preservative [1] | N/A | 10 mg/mL [1] | 50 mg:<br>discard unused portion [1,2]<br><br>200 mg,1000 mg:<br>8 h F [1,2] | syringe | 8 h RT [1,2] | |
| | | | | 0.05-10 mg/mL<br>NS, D5W, Ringer's, LR, D10W, D5-NS [1,2]<br><br>50-250 mL† | **NS**, D5W, LR, Ringer's:<br>24 h RT [1]<br><br>D10W, D5-NS:<br>8 h RT [1] | |
| **Leucovorin**<br>50 mg/5 mL<br>500 mg/50 mL<br>(Pfizer/Hospira)<br>(F)(PFL)<br>no preservative [3] | N/A | 10 mg/mL [3] | 8 h [3] | syringe | 8 h RT [3] | |
| | | | | 0.05–10 mg/mL<br>**NS**, D5W, LR, Ringer's, D10W, D5NS [3]<br><br>50-250 mL† | **NS**, D5W, LR, Ringer's:<br>24 h RT [3]<br><br>D10W, D5NS:<br>8 h RT [3] | |




Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Leucovorin**<br>50 mg/5 mL<br>500 mg/50 mL<br>(Teva)<br>(F)(PFL)<br>no preservative [4] | N/A | 10 mg/mL [5] | discard unused portion [5] | syringe | 8 h [6,7] | |
| | | | | 0.4 - 4.8 mg/mL<br>**NS**, D5W [8]<br><br>50-250 mL† | 72 h **F**, RT [8] | |
| | | | | 0.06 - 0.4 mg/mL<br>**NS**, D5W [4]<br><br>50-250 mL† | **NS**:<br>24 h RT [4]<br><br>D5W:<br>12 h RT [4] | |
| | | | | 0.06 - 1 mg/mL<br>Ringer's, Lactated Ringer's, D10W, D10-NS [4] | Ringer's, LR:<br>24 h RT [4]<br><br>D10W:<br>12 h RT [4]<br><br>D10NS:<br>6 h RT [4] | |




Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Lurbinectedin**<br>4 mg<br>(Jazz)<br>(F)<br>no preservative [9] | 8 mL SWI [9] | 0.5 mg/mL [9] | 12 h **F**, RT [9,10] | 100-250 mL<br>**NS**, D5W [9] | complete administration within 24 h **F**, RT [9] | - larger infusion volume is recommended for peripheral line [9]<br>- do not use nylon membrane filters for administration if diluted in NS [9]; BD Alaris pumps and syringe sets have polyethersulfone membrane in-line filters [11] |
| **Lurbinectedin**<br>4 mg<br>(Pharma Mar)<br>(F)<br>no preservative [12]<br>(SAP) | 8 mL SWI [12] | 0.5 mg/mL [12] | 12 h **F**, RT [10,12] | 100–250 mL<br>**NS**, D5W [12] | 30 h **F**, RT [12] | - larger infusion volume is recommended for peripheral line [12] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Melphalan**<br>50 mg<br>(Marcan)<br>(RT)(PFL)<br>no preservative [13] | 10 mL supplied diluent [13]<br><br>rapidly add diluent and immediately shake vigorously to dissolve [13]<br><br>record time of reconstitution | 5 mg/mL [13] | 2 h RT [13]<br><br>**do NOT refrigerate** [13] | 0.1-0.45 mg/mL<br>**NS** only [13] | complete administration within 50 min RT from time of initial reconstitution [13] | - will precipitate if stored in fridge [13] |
| **Melphalan**<br>50 mg<br>(Taro)<br>(RT)(PFL)<br>no preservative [14] | 10 mL supplied diluent [14]<br><br>rapidly add diluent and immediately shake vigorously to dissolve [14]<br><br>record time of reconstitution | 5 mg/mL [14] | 2 h RT [14]<br><br>**do NOT refrigerate** [14] | 0.1-0.45 mg/mL<br>**NS** only [14] | complete administration within 50 min RT from time of initial reconstitution [14] | - will precipitate if stored in fridge [14] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Mesna**<br>400 mg/4 mL<br>1000 mg/10 mL<br>(Baxter)<br>(RT)<br>no preservative [15] | N/A | 100 mg/mL [15]<br><br>(use filter needle to withdraw from ampoule) | discard unused portion [15] | ≥1 mg/mL<br>**NS**, D5W,<br>D5½-NS, LR [15-17]<br><br>100 mL† | 24 h RT [15] | |
| **Mesna**<br>1000 mg/10 mL<br>5000 mg/50 mL<br>(Baxter)<br>(RT)<br>preservative [15] | N/A | 100 mg/mL [15] | 8 d RT [15]<br><br>(vial may be punctured up to 4 times) [15] | ≥1 mg/mL<br>**NS**, D5W,<br>D5½-NS, LR [15-17]<br><br>100 mL† | 24 h RT [15] | |
| **Mesna**<br>1000 mg/10 mL<br>(Fresenius Kabi)<br>(RT)<br>preservative [18] | N/A | 100 mg/mL [18] | 14 d **F, R**T[10,18] | ≥1 mg/mL<br>**NS**, D5W [19]<br><br>100 mL† | 48 h F, 24 h RT [18] | |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Methotrexate**<br>50 mg/2 mL<br>500 mg/20 mL<br>1 g/40 mL<br>(Accord)<br>(RT)(PFL)<br>no preservative [20] | N/A | 25 mg/mL [20] | 50mg:<br>discard unused portion [20]<br><br>500 mg, 1 g:<br>8 h RT [20] | syringe | use within<br>8 h RT<br>of initial puncture [20] | - for high-dose regimens (e.g., 1-12 g/m$^2$ as a single dose): use preservative-free methotrexate [20]<br>- do not use for IT injection |
| | | | | 0.4–2 mg/mL<br>**NS**, D5W [20]<br><br>50-500 mL† | use within<br>24 h RT<br>of initial puncture [20]<br><br>**(PFL) | |
| | | | | high dose<br>(e.g., 1-12 g/m$^2$<br>as a single dose):<br>1000 mL* NS | use within<br>24 h RT<br>of initial puncture [20]<br><br>**(PFL) | |
| **Methotrexate**<br>**<u>intravitreal injection</u>**<br>50 mg/2 mL<br>(Accord)<br>(RT)(PFL)<br>no preservative [20] | N/A | 25 mg/mL [20] | discard unused portion [20] | syringe<br>for<br>intravitreal use | use within 4 h<br>of initial puncture [10] | - for intravitreal use preservative-free methotrexate is preferred [21] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Methotrexate**<br>**<u>IT Injection</u>**<br>only preservative free methotrexate may be administered by the intrathecal route [22]<br>50 mg/2 mL<br>(Accord)<br>(RT)(PFL)<br>no preservative [20] | N/A | 25 mg/mL [20] | discard unused portion [20] | IT syringe<br><br>qs to 6 mL with preservative free NS [23,24]<br><br>diluents containing preservatives should **NOT** be used for intrathecal administration [25] | use within 4 h of initial puncture [10] | - auxiliary info [10]: IT<br>- label to include route in full (i.e., INTRATHECAL injection) attached to both syringe and outer Ziploc bag [26] |
| **Methotrexate**<br>50 mg/2 mL<br>500 mg/20 mL<br>(Accord)<br>(RT)(PFL)<br>preservative [20] | N/A | 25 mg/mL [20] | 28 d F [10,20] | syringe | 10 d **F** [10,20] | - contains benzyl alcohol [20]<br>- do NOT use for high-dose regimens (e.g., 1-12 g/m$^2$ as a single dose) [20]<br>- do NOT use for IT injection [20] |
| | | | | 0.4–2 mg/mL **NS**, D5W [20]<br><br>50-500 mL† | 24 h RT [20] | |




Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Methotrexate**<br>1 g<br>(Fresenius Kabi USA)<br>(RT)(PFL)<br>no preservative [27] | 39.4 mL<br>NS, D5W [28] | 25 mg/mL [28] | discard unused portion [27] | syringe | use within<br>4 h<br>of initial puncture [10] | - for high-dose regimens (e.g., 1-12 g/m$^2$ as a single dose): use preservative-free methotrexate |
| | | | | 0.4–2 mg/mL<br>**NS**, D5W [20]<br><br>50-500 mL† | use within<br>4 h<br>of initial puncture [10] | |
| | | | | high dose<br>(e.g., 1-12 g/m$^2$<br>as a single dose):<br>1000 mL*<br>D5W [27], NS [20] | use within<br>4 h<br>of initial puncture [10] | |
| **Methotrexate**<br>**<u>intravitreal injection</u>**<br>1 g<br>(Fresenius Kabi USA)<br>(RT)(PFL)<br>no preservative [27] | 39.4 mL<br>NS, D5W [28] | 25 mg/mL [28] | discard unused portion [27] | syringe<br>for<br>intravitreal use | use within<br>4 h<br>of initial puncture [10] | - for intravitreal use preservative-free methotrexate is preferred [21] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Methotrexate**<br>**IT Injection**<br>Only preservative free methotrexate may be administered by the intrathecal route [22]<br>1 g<br>(Fresenius Kabi USA)<br>(RT)(PFL)<br>no preservative [27] | 39.4 mL<br>NS, D5W [28] | 25 mg/mL [28] | discard unused portion [27] | IT syringe<br><br>qs to 6 mL with preservative free NS [23,24]<br><br>diluents containing preservatives should **NOT** be used for intrathecal administration [25] | use within<br>4 h<br>of initial puncture [10] | - auxiliary info [10]: IT<br>- label to include route in full (i.e., INTRATHECAL injection) attached to both syringe and outer Ziploc bag [26] |
| **Methotrexate**<br>50 mg/2 mL<br>500 mg/20 mL<br>1 g/40 mL<br>2.5 g/100 mL<br>(Pfizer/Hospira)<br>(RT)(PFL)<br>no preservative [29] | N/A | 25 mg/mL [29] | 50mg:<br>discard unused portion [29]<br><br>500 mg, 1 g, or 2.5 g:<br>8 h RT [29] | syringe | use within<br>8 h RT<br>of initial puncture [29] | - for high-dose regimens (e.g., 1-12 g/m$^2$ as a single dose): use preservative-free methotrexate [29]<br>- do not use for IT injection |
| | | | | 0.4–2 mg/mL<br>**NS**, D5W [29]<br><br>50-500 mL† | use within<br>24 h RT<br>of initial puncture [29]<br><br>**(PFL) | |
| | | | | high dose<br>(e.g., 1-12 g/m$^2$ as a single dose):<br>1000 mL* NS | use within<br>24 h RT<br>of initial puncture [29]<br><br>**(PFL) | |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Methotrexate**<br>**intravitreal injection**<br>50 mg/2 mL<br>(Pfizer/Hospira)<br>(RT)(PFL)<br>no preservative [29] | N/A | 25 mg/mL [29] | discard unused portion [29] | syringe<br>for<br>intravitreal use | use within 4 h of initial puncture [10] | - for intravitreal use preservative-free methotrexate is preferred [21] |
| **Methotrexate**<br>**IT Injection**<br>only preservative free methotrexate may be administered by the intrathecal route [22]<br>50 mg/2 mL<br>(Pfizer/Hospira)<br>(RT)(PFL)<br>no preservative [29] | N/A | 25 mg/mL [29] | discard unused portion [29] | IT syringe<br><br>qs to 6 mL with preservative free NS [23,24]<br><br>diluents containing preservatives should **NOT** be used for intrathecal administration [25] | use within<br>4 h<br>of initial puncture [10] | - auxiliary info [10]: IT<br>- label to include route in full (i.e., INTRATHECAL injection) attached to both syringe and outer Ziploc bag [26] |
| **Methotrexate**<br>50 mg/2 mL<br>500 mg/20 mL<br>(Pfizer/Hospira)<br>(RT)(PFL)<br>preservative [29] | N/A | 25 mg/mL [29] | 28 d F [10,29] | syringe | 10 d **F** [10,29] | - contains benzyl alcohol [29]<br>- do NOT use for high-dose regimens (e.g., 1-12 g/m$^2$ as a single dose) [29]<br>- do NOT use for IT injection [29] |
| | | | | 0.4–2 mg/mL<br>**NS**, D5W [29]<br><br>50-500 mL† | 24 h RT [29] | |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Mirvetuximab soravtansine**<br>100 mg<br>(AbbVie EU)<br>(F)(PFL)<br>do not shake<br>no preservative[30]<br>(SAP) | n/a | 5 mg/mL[30]<br><br>allow vials to reach RT before using[30] | discard unused portion[30] | dilute with D5W in empty infusion bag to final concentration of 1-2 mg/mL [30]<br><br>qs to 200-600 mL†<br><br>do not use NS[30]<br><br>gently invert to mix; do not shake[30] | 8 h RT<br>or<br>24 h F<br>plus an additional 8 h RT, including infusion[30]<br><br>if refrigerated, bring bag to RT prior to administration[30] | - incompatible with saline[30]<br>- do not use if discoloured or cloudy, or has particulates[30]<br>- use non-DEHP bag and tubing[30]<br>- administer using 0.2 micron in-line filter[30] |
| **Mitomycin**<br>20 mg<br>(Accord)<br>(RT)(PFL)<br>no preservative [31] | 40 mL SWI [31]<br><br>shake well [31] | 0.5 mg/mL [31] | 12 h F,<br>6 h RT [10,31]<br><br>**(PFL) [31] | syringe | 72 h F, 6 h RT [31]<br><br>**(PFL) [31] | |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Mitomycin <u>intravesical</u>**<br>20 mg<br>(Accord)<br>(RT)(PFL)<br>no preservative [31] | 40 mL SWI [31]<br>shake well [31] | 0.5 mg/mL [31] | 12 h F,<br>6 h RT [10,31]<br>**(PFL) [31] | syringe | 72 h F, 6 h RT [31]<br>**(PFL) [31] | |
| | 10 mL SWI [32]<br>shake well [31] | 2 mg/mL [32] | use immediately after preparation to prevent precipitation [33] | syringe | use immediately after preparation to prevent precipitation [33] | - may precipitate due to low solubility [33,34]<br>- do NOT refrigerate [33] |
| | 25 mL SWI<br>shake well | 0.8 mg/mL [35] | discard unused portion [2,35]<br>**(PFL) [2,35] | syringe | 4 days RT [35]<br>**(PFL) [2,35] | - do NOT refrigerate [35] |
| | 33.3 mL SWI<br>shake well | 0.6 mg/mL [35] | discard unused portion [2,35]<br>**(PFL) [2,35] | syringe | 4 days **F**, RT [35]<br>**(PFL) [2,35] | |
| **Mitomycin <u>intraperitoneal</u>**<br>20 mg<br>(Accord)<br>(RT)(PFL)<br>no preservative [31] | 40 mL SWI [31]<br>shake well [31] | 0.5 mg/mL [31] | 12 h F,<br>6 h RT [10,31]<br>**(PFL) [31] | 0.02-0.04 mg/mL<br>**NS**, sodium lactate [31] | NS [31]:<br>18 h F, 3 h RT<br>sodium lactate [31]:<br>6 h F, 3 h RT | |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Mitomycin**<br>20 mg<br>(Hikma)<br>(RT)(PFL)<br>no preservative [36] | 40 mL SWI [36]<br>shake well [36] | 0.5 mg/mL [36] | 12 h F,<br>6 h RT [10,36]<br>**(PFL) [36] | syringe | 72 h F, 6 h RT [36]<br>**(PFL) [36] | |
| **Mitomycin**<br>**intravesical**<br>20 mg<br>(Hikma)<br>(RT)(PFL)<br>no preservative [36] | 40 mL SWI [36]<br>shake well [36] | 0.5 mg/mL [36] | 12 h F,<br>6 h RT [10,36]<br>**(PFL) [36] | syringe | 72 h F, 6 h RT [36]<br>**(PFL) [36] | |
| | 10 mL SWI [32]<br>shake well | 2 mg/mL [32] | use immediately after preparation to prevent precipitation [33] | syringe | use immediately after preparation to prevent precipitation [33] | - may precipitate due to low solubility [33,34]<br>- do NOT refrigerate [33] |
| | 25 mL SWI<br>shake well | 0.8 mg/mL [35] | discard unused portion [10,35]<br>**(PFL) [10,35] | syringe | 4 days RT [35]<br>**(PFL) [10,35] | - do NOT refrigerate [35] |
| | 33.3 mL SWI<br>shake well | 0.6 mg/mL [35] | discard unused portion [10,35]<br>**(PFL) [10,35] | syringe | 4 days **F**, RT [35]<br>**(PFL) [10,35] | |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Mitomycin intraperitoneal**<br>20 mg<br>(Hikma)<br>(RT)(PFL)<br>no preservative [36] | 40 mL SWI [36]<br><br>shake well [36] | 0.5 mg/mL [36] | 12 h F,<br>6 h RT [10,36]<br><br>**(PFL) [36] | 0.02-0.04 mg/mL<br>**NS** [36] | NS [36]:<br>18 h F, 3 h RT | |
| **Mitomycin**<br>20 mg<br>(Teva)<br>(RT)(PFL)<br>no preservative [37] | 40 mL SWI [37]<br><br>shake well [37] | 0.5 mg/mL [37] | 12 h F,<br>6 h RT [10,37]<br><br>**(PFL) [37] | syringe | 72 h F, 6 h RT [37]<br><br>**(PFL) [37] | |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Mitomycin <u>intravesical</u>**<br>20 mg<br>(Teva)<br>(RT)(PFL)<br>no preservative [37] | 40 mL SWI [37]<br>shake well [37] | 0.5 mg/mL [37] | 12 h F,<br>6 h RT [10,37]<br>**(PFL) [37] | syringe | 72 h F, 6 h RT [37]<br>**(PFL) [37] | |
| | 10 mL SWI [32]<br>shake well [37] | 2 mg/mL [32] | use immediately after preparation to prevent precipitation [33] | syringe | use immediately after preparation to prevent precipitation [33] | - may precipitate due to low solubility [33,34]<br>- do NOT refrigerate [33] |
| | 25 mL SWI<br>shake well | 0.8 mg/mL [35] | discard unused portion [2,35]<br>**(PFL) [2,35] | syringe | 4 days RT [35]<br>**(PFL) [2,35] | - do NOT refrigerate [35] |
| | 33.3 mL SWI<br>shake well | 0.6 mg/mL [35] | discard unused portion [2,35]<br>**(PFL) [2,35] | syringe | 4 days **F**, RT [35]<br>**(PFL) [2,35] | |
| **Mitomycin <u>intraperitoneal</u>**<br>20 mg<br>(Teva)<br>(RT)(PFL)<br>no preservative [37] | 40 mL SWI [37]<br>shake well [37] | 0.5 mg/mL [37] | 12 h F,<br>6 h RT [10,37]<br>**(PFL) [37] | 0.02-0.04 mg/mL<br>**NS**, sodium lactate [37] | NS [37]:<br>18 h F, 6 h RT<br>sodium lactate [37]:<br>6 h **F**, RT | |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **mitoXANTRONE**<br>20 mg/10 mL<br>(Fresenius Kabi)<br>(RT)<br>no preservative [38] | N/A | 2 mg/mL [38] | discard unused portion [38] | 0.2-0.6 mg/mL<br>**NS**, D5W [38]<br><br>50 mL† | 24 h RT [38] | |
| **mitoXANTRONE**<br>20 mg/10 mL<br>25 mg/12.5 mL<br>30 mg/15 mL<br>(Pfizer/Hospira)<br>(RT)(PFL)<br>no preservative [39] | N/A | 2 mg/mL [39] | discard unused portion [39] | 0.2-0.6 mg/mL<br>**NS**, D5W [39]<br><br>50 mL† | 72 h F, 24 h RT [39]<br><br>**(PFL) [39] | |
| **Mogamulizumab**<br>20 mg/5 mL<br>(Kyowa)<br>(F)(PFL)<br>do not shake<br>no preservative [40] | N/A | 4 mg/mL [40] | discard unused portion [40] | 0.1-3 mg/mL NS<br><br>100 mL*<br><br>mix by gentle inversion;<br>do not shake [40] | 24 h F [40] | - discard if cloudy, discoloured, or visible particulates are present [40]<br>- administer with 0.2 micron in-line filter [40] |
| **Nelarabine**<br>250 mg/50 mL<br>(Sandoz)<br>(RT)<br>no preservative [41] | N/A | 5 mg/mL [41] | discard unused portion [41] | undiluted in empty PVC infusion bag or glass container [41] | 8 h RT [41] | - discard if discoloured, hazy, or particulates are present [41] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Nivolumab**<br>40 mg/4 mL<br>100 mg/10 mL<br>(BMS)<br>(F)(PFL)<br>do not shake<br>no preservative [42] | N/A | 10 mg/mL [42] | discard unused portion [42] | 1-10 mg/mL<br>**NS**, D5W [42]<br><br>25-100 mL†<br><br>mix by gentle inversion;<br>do not shake [42]<br><br>OR<br>undiluted in empty infusion bag<br>or glass container [42] | complete administration within 7 days F, including max 8 h at RT [42]<br><br>**(PFL) [42]<br><br>(can be in room light when at RT) [42] | - do not shake [42]<br>- administer with 0.2 micron in-line filter [42]<br>- may contain a few amorphous particles [42]<br>- discard if cloudy, has pronounced colour change (should be clear to pale yellow) [42] |
| **Nivolumab-relatlimab**<br>240 mg-80 mg/20 mL<br>(BMS)<br>(F)(PFL)<br>do not shake<br>no preservative [43] | N/A | 12 mg/mL nivolumab-4 mg/mL relatlimab | discard unused portion [43] | 3-12 mg/mL nivolumab<br><br>50-100 mL†<br>**NS**, D5W [43]<br><br>mix by gentle inversion; do not shake [43]<br><br>(OR undiluted in empty infusion bag or glass container [43]) | complete administration within 24 h F, 8 h RT [43]<br><br>**(PFL) [43]<br><br>(can be in room light when at RT) [43] | - do not shake [43]<br>- administer with a 0.2 micron in-line filter [43]<br>- discard if cloudy, discoloured or contains particulates [43]<br>- may contain a few translucent-to-white particles [43] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **oBINutuzumab**<br>1000 mg/40 mL<br>(Roche)<br>(F)(PFL)<br>do not shake<br>no preservative [44] | N/A | 25 mg/mL [44] | discard unused portion [45] | **NS**<br><br>100 mg:<br>100 mL [44]<br><br>900 mg:<br>250 mL [44]<br><br>1000 mg:<br>250 mL [44]<br><br>do NOT use dextrose containing solutions [44] | 24 h **F**, 48 h RT [44,46] | - once removed from the fridge, diluted product is stable for an additional 48 h RT [44,46]<br>- do NOT shake [44] |
| **Octreotide**<br>50 mcg/1 mL<br>100 mcg/1 mL<br>500 mcg/1 mL<br>(Omega)<br>(F)(PFL)<br>no preservative [47] | N/A | 50 mcg/mL [47]<br><br>100 mcg/mL [47]<br><br>500 mcg/mL [47] | discard unused portion [47] | NS [47]<br><br>volume adjusted to ensure a continuous infusion of octreotide at 25 mcg/h [47] | 24 h RT [47] | |




Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Octreotide**<br>multidose vial:<br>1000 mcg/5 mL<br>(Omega)<br>(F)(PFL)<br>preservative [47] | N/A | 200 mcg/mL [47] | 15 d F [47] | NS [47]<br><br>volume adjusted to ensure a continuous infusion of octreotide at 25 mcg/h [47] | 24 h RT [47] | |
| **Octreotide**<br>(SANDOSTATIN®)<br>50 mcg/1 mL<br>100 mcg/1 mL<br>500 mcg/1 mL<br>(Novartis)<br>(F)(PFL)<br>no preservative [48] | N/A | 50 mcg/mL [48]<br>100 mcg/mL [48]<br>500 mcg/mL [48] | discard unused portion [48] | NS [48]<br><br>volume adjusted to ensure a continuous infusion of octreotide at 25 mcg/h [48] | 24 h RT [48] | |
| **Octreotide**<br>(SANDOSTATIN®)<br>multi-dose vial:<br>1000 mcg/5 mL<br>(Novartis)<br>(F)(PFL)<br>preservative [48] | N/A | 200 mcg/mL [48] | 14 d **F**, RT [48] | NS [48]<br><br>volume adjusted to ensure a continuous infusion of octreotide at 25 mcg/h [48] | 24 h RT [48] | |
| **Octreotide**<br>(SANDOSTATIN LAR®)<br>(long acting)<br>10 mg | 2 mL supplied diluent [48] | 10 mg:<br>5 mg/mL [48] | discard unused portion [48] | syringe<br>(for deep intragluteal administration only) [48] | use within<br>4 h<br>of initial | - do NOT shake [48] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| 20 mg<br>30 mg<br>(Novartis)<br>(F)(PFL)<br>no preservative [48] | add diluent:<br>gently run diluent down sides of vial [48]<br><br>do NOT disturb for 2–5 min; then swirl moderately [48]<br><br>record time of reconstitution | 20 mg:<br>10 mg/mL [48]<br><br>30 mg:<br>15 mg/mL [48] | | | reconstitution [10,48] | |
| **Octreotide suspension**<br>(long acting)<br>10 mg<br>20 mg<br>30 mg<br>(Teva)<br>(F)(PFL) | 2 mL supplied diluent<br><br>let stand at RT for 30 min prior to reconstitution [49] | 10 mg:<br>5 mg/mL [49]<br><br>20 mg:<br>10 mg/mL [49] | discard unused portion [49] | syringe<br>(for deep intragluteal administration only) [49] | use within<br>4 h<br>of initial reconstitution [10,49] | - gently shake to resuspend before administration [49]<br>- delay in administration may result in sedimentation [49] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| no preservative [49] | add supplied diluent [49]<br><br>let vial stand for 5 min after adding diluent to saturate powder [49]<br><br>shake moderately in horizontal direction for ≥30 sec to create suspension [49]<br><br>record time of reconstitution | 30 mg:<br>15 mg/mL [49] | | | | |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Oxaliplatin**<br>50 mg/10 mL<br>100 mg/20 mL<br>200 mg/40 mL<br>(Dr. Reddy's)<br>(RT)(PFL)<br>no preservative [50] | N/A | 5 mg/mL [50] | discard unused portion [50] | 0.2-0.7 mg/mL<br>**D5W** [50]<br><br>100-500 mL†<br><br>do **NOT** use NS or other chloride-containing solution [50]<br><br>do **NOT** use aluminum-containing needle and syringe [50] | 0.2-2 mg/mL:<br>48 h F, 24 h RT [50] | - do **NOT** use aluminum-containing needle, syringe, or tubing [50] |
| **Oxaliplatin**<br>50 mg/10 mL<br>100 mg/20 mL<br>200 mg/40 mL<br>(Pfizer/Hospira)<br>(RT)<br>no preservative [51] | N/A | 5 mg/mL [51] | discard unused portion [51] | 0.2-0.7 mg/mL<br>**D5W** [51]<br><br>100-500 mL†<br><br>do **NOT** use NS or other chloride-containing solutions [51]<br><br>do **NOT** use aluminum-containing needle and syringe [51] | **0.2-0.4 mg/mL:**<br>24 h RT [51]<br>or<br>5 d F<br>plus an additional<br>8 h RT [52]<br><br>**0.5–2 mg/mL:**<br>24 h RT [51]<br>or<br>10 d F,<br>plus an additional<br>8 h RT [10,52]<br><br>**(PFL)<br>when stored in F [52] | - do **NOT** use aluminum-containing needle, syringe, tubing [51] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Oxaliplatin**<br>50 mg/10 mL<br>100 mg/20 mL<br>150 mg/30 mL<br>200 mg/40 mL<br>(Sandoz)<br>(RT)(PFL)<br>no preservative [53] | N/A | 5 mg/mL [53] | 12 h **F**, RT [10,54] | 0.2-0.7 mg/mL<br>**D5W** [53]<br><br>100-500 mL†<br><br>do **NOT** use NS or other chloride-containing solution [53]<br><br>do **NOT** use aluminum-containing needle and syringe [53] | 0.2-2 mg/mL:<br>48 h F, 24 h RT [53] | - do **NOT** use aluminum-containing needle, syringe, tubing [53] |
| **Oxaliplatin**<br>50 mg/10 mL<br>100 mg/20 mL<br>200 mg/40 mL<br>(Teva)<br>(RT)(PFL)<br>no preservative [55] | N/A | 5 mg/mL [55] | discard unused portion [55] | 0.2-0.7 mg/mL<br>**D5W** [55]<br><br>100-500 mL†<br><br>do **NOT** use NS or other chloride-containing solution [55]<br><br>do **NOT** use aluminum-containing needle and syringe [55] | 0.2-2 mg/mL:<br>48 h F, 24 h RT [55] | - do **NOT** use aluminum-containing needle, syringe or tubing [55] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **PACLitaxel**<br>30 mg/5 mL<br>100 mg/16.7 mL<br>300 mg/50 mL<br>(Accord)<br>(RT)(PFL)<br>preservative [56] | N/A | 6 mg/mL [56] | 30 mg, 100 mg:<br>28 d RT [10,56]<br><br>300 mg:<br>24 h RT [10,56] | 0.3-1.2 mg/mL<br>**NS**, D5W, D5NS, D5LR [56]<br><br>50-500 mL† | complete administration within 27 h RT [56] | - use non-DEHP bag and tubing [56]<br>- administer with 0.2 micron in-line filter [56]<br>- avoid excessive shaking [56] |
| | | | | 0.1 mg/mL **NS** [57] | 44 h **F**, RT [57] | |
| **PACLitaxel**<br>30 mg/5 mL<br>100 mg/16.7 mL<br>300 mg/50 mL<br>(Biolyse)<br>(RT)<br>preservative [58] | N/A | 6 mg/mL [58] | 28 d RT [59] | 0.3-1.2 mg/mL<br>**NS,** D5W [58]<br><br>50-500 mL† | complete administration within 27 h RT [60,61] | - use non-DEHP bag and tubing [58]<br>- administer with 0.2 micron in-line filter [58] |
| | | | | 0.1 mg/mL **NS** [57] | 44 h **F**, RT [57] | |
| | | | | 0.012-0.12 mg/mL<br>**NS** [62] | 16 h RT [60] | |
| | | | | devices with spikes (e.g., chemo dispensing pins) **may be used** with vials [63] | | |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Paclitaxel**<br>30 mg/5 mL<br>100 mg/16.7 mL<br>300 mg/50 mL<br>(Sandoz)<br>(RT)(PFL)<br>preservative [64] | N/A | 6 mg/mL [64] | 30 mg, 100 mg:<br>28 d RT [10,64]<br><br>300 mg:<br>24 h RT [10,64] | 0.3-1.2 mg/mL<br>**NS**, D5W, D5NS [64]<br><br>50-500 mL†* | complete administration within 27 h RT [64] | - use non-DEHP bag and tubing [64]<br>- administer with 0.2 micron inline filter [64]<br>- avoid excessive shaking [64] |
| | | | | 0.1 mg/mL **NS** [57] | 44 h **F**, RT [57] | |
| **PACLitaxel, nanoparticle, albumin-bound (NAB)**<br>100 mg<br>(BMS/Celgene)<br>(RT)(PFL)<br>no preservative [65] | 20 mL NS[65]<br><br>slowly direct diluent against side of vial (i.e., ≥1 min) during reconstitution [65]<br><br>let stand for ≥5 min to wet powder [65]<br><br>gently swirl or invert for ≥2 min [65] | 5 mg/mL [65] | use immediately (RT)<br>or<br>8 h F [65]<br><br>**(PFL) [65] | undiluted in empty PVC, non-PVC, or non-DEHP infusion bag [65] | 48 h F<br>plus an additional 8 h RT [66] | - each vial contains 900 mg human albumin [65]<br>- to prevent foaming, do NOT inject NS directly onto the powder [65]<br>- some settling may occur; use mild agitation to resuspend [65]<br>- administer with 15 micron filter ONLY [65] (NOTE: filters with pore size less than 15 microns may cause filter blockage) [65] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **PACLitaxel, nanoparticle, albumin-bound (NAB)**<br>100 mg<br>(Panacea/Apo)<br>(RT)(PFL)<br>no preservative [67] | 20 mL NS [67]<br><br>slowly direct diluent against side of vial (i.e., ≥1 min) during reconstitution [67]<br><br>let stand for ≥5 min to wet powder [67]<br><br>gently swirl or invert for ≥2 min [67]<br><br>(if foaming occurs, let stand for ≥15 min) [67] | 5 mg/mL [67] | use immediately (RT)<br>or<br>8 h F [67]<br><br>**(PFL) [67] | undiluted in empty PVC, non-PVC, or non-DEHP infusion bag [67] | 56 h F<br>plus an additional 4 h RT [68] | - each vial contains 900 mg human albumin [67]<br>- to prevent foaming, do NOT inject NS directly onto the powder [67]<br>- some settling may occur; use gentle inversion to resuspend [67]<br>- discard if visible particulates are present [67]<br>- administer with 15 micron filter ONLY [67] |
| **Pamidronate**<br>30 mg/10 mL<br>60 mg/10 mL<br>90 mg/10 mL<br>(Fresenius Kabi)<br>(RT)<br>no preservative [69] | N/A | 3 mg/mL [69]<br><br>6 mg/mL [69]<br><br>9 mg/mL [69] | discard unused portion [69] | ≤0.36 mg/mL [69]<br>**NS**, D5W [69]<br><br>250 mL† | 24 h RT [69] | - do **NOT** mix with calcium containing solutions (e.g., LR) [69] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Pamidronate**<br>30 mg/10 mL<br>60 mg/10 mL<br>90 mg/10 mL<br>(Hospira)<br>(RT)<br>no preservative [70] | N/A | 3 mg/mL [70]<br>6 mg/mL [70]<br>9 mg/mL [70] | discard unused portion [70] | 0.06–0.36 mg/mL **NS**, D5W [70]<br>250 mL† | 24 h F<br>plus an additional 24 h RT<br>(total 48 h) [70]<br>**(PFL) [70] | - do **NOT** mix with calcium containing solution (e.g., LR) [70] |
| **Pamidronate**<br>30 mg/10 mL<br>60 mg/10 mL<br>90 mg/10 mL<br>(Omega)<br>(RT)<br>no preservative [71] | N/A [71] | 3 mg/mL [71]<br>6 mg/mL [71]<br>9 mg/mL [71] | discard unused portion [71] | 0.06–0.36 mg/mL **NS**, D5W [71]<br>250 mL† | 24 h F<br>plus an additional 24 h RT<br>(total 48 h) [71]<br>**(PFL) [71] | - do **NOT** mix with calcium containing solution (e.g., LR) [71] |
| **Pamidronate**<br>30 mg/10 mL<br>60 mg/10 mL<br>90 mg/10 mL<br>(Pfizer)<br>(RT)<br>no preservative [72] | N/A | 3 mg/mL [72]<br>6 mg/mL [72]<br>9 mg/mL [72] | discard unused portion [72] | 0.06-0.36 mg/mL **NS**, D5W [72]<br>250 mL† | 24 h F<br>plus an additional 24 h RT<br>(total 48 h) [72]<br>**(PFL) [72] | - do **NOT** mix with calcium containing solution (e.g., LR) [72] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Pamidronate**<br>30 mg/10 mL<br>60mg/10 mL<br>90 mg/10 mL<br>(Sandoz Canada)<br>RT<br>no preservative [73] | N/A | 3 mg/mL [73]<br>6 mg/mL [73]<br>9 mg/mL [73] | discard unused portion [73,74] | **NS**; D5W [73]<br>250 mL† | 24 h RT [73] | - do **NOT** mix with calcium containing solution (e.g., LR) [73] |
| **PANitumumab**<br>100 mg/5 mL<br>400 mg/20 mL<br>(Amgen)<br>(F)(PFL)<br>do not shake<br>no preservative [75] | N/A | 20 mg/mL [75] | discard unused portion [75] | 1-10mg/mL NS [75]<br>100 mL† | 24 h F, 6 h RT [75-78] | - administer with 0.2 micron in-line filter [75]<br>- solution may contain particulates which do not affect product quality [75]<br>- do not administer if discoloured [75] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Pegaspargase**<br>(pegylated asparaginase *E. coli*)<br>3750 units/5 mL<br>(Servier)<br>(F)(PFL)<br>do not shake<br>no preservative [79] | N/A | 750 units/mL [79] | discard unused portion [79] | IM [79]:<br>max volume:<br>2 mL in children and adolescents;<br>3 mL in adults<br><br>if volume greater than above, use multiple sites [79] | syringe:<br>use within<br>4 h<br>of vial puncture [2,79] | - do NOT shake [79] |
| | | | | IV [79]:<br>100 mL **NS**, D5W | bag:<br>use within<br>4 h<br>of vial puncture [2,79] | |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Pegaspargase**<br>(pegylated asparaginase *E. coli*)<br>3750 units/5 mL<br>(Servier **USA**)<br>(F)(PFL)<br>do not shake<br>no preservative [79,80] | N/A | 750 units/mL [79] | discard unused portion [79] | IM [79]:<br>max volume:<br>2 mL in children and adolescents;<br>3 mL in adults<br><br>if volume greater than above, use multiple sites [79] | syringe:<br>use within<br>4 h<br>of vial puncture [2,79] | - do NOT shake [79] |
| | | | | IV [79]:<br>100 mL **NS**, D5W | bag:<br>use within<br>4 h<br>of vial puncture [2,79] | |
| **Pembrolizumab**<br>100 mg/4 mL<br>(Merck)<br>(F)(PFL)<br>do not shake<br>no preservatives [81] | N/A | 25 mg/mL [81] | discard unused portion [2,81] | 1-10 mg/mL<br>**NS**, D5W [81]<br><br>50 mL*<br><br>mix by gentle inversion [81] | complete administration within 96 h F, 6 h RT [81] | - administer with 0.2 micron in-line filter [81]<br>- bring vials and diluted solutions to RT prior to use [81]<br>- vials contain 0.25 mL overfill [81] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Pemetrexed**<br>100 mg<br>500 mg<br>(Accord)<br>(RT)<br>no preservative [82] | 100 mg:<br>4.2 mL NS [82]<br><br>500 mg:<br>20 mL NS [82] | 25 mg/mL [82] | 12 h **F**, RT [10,82] | 100 mL NS [82] | 24 h **F**, RT [82] | - do **NOT** mix with calcium containing solution<br>(e.g., LR) [82] |
| **Pemetrexed**<br>100 mg/4 mL<br>500 mg/20 mL<br>1000 mg/40 mL<br>(Accord)<br>(RT)(PFL)<br>no preservative [83] | N/A | 25 mg/mL [83] | discard unused portion [83] | 100 mL NS [83] | 24 h F [83] | - do **NOT** mix with calcium containing solution<br>(e.g., LR) [83] |
| **Pemetrexed**<br>100 mg<br>500 mg<br>(Dr. Reddy's)<br>(RT)<br>no preservative [84] | 100 mg:<br>4.2 mL NS [84]<br><br>500 mg:<br>20 mL NS [84] | 25 mg/mL [84] | 12 h **F**, RT [10,85-87] | 100 mL NS [84] | 24 h **F**, RT [85-87] | - do **NOT** mix with calcium containing solution<br>(e.g., LR) [84] |
| **Pemetrexed**<br>100 mg<br>500 mg<br>(Lilly)<br>(RT)<br>no preservative [88] | 100 mg:<br>4.2 mL NS [88]<br><br>500 mg:<br>20 mL NS [88] | 25 mg/mL [88] | 12 h **F** [10,88] | 100 mL NS [88] | 24 h **F** [88] | - do **NOT** mix with calcium containing solution<br>(e.g., LR) [88] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Pemetrexed**<br>100 mg<br>500 mg<br>1000 mg<br>(Taro)<br>(RT)<br>no preservative [89] | 100 mg:<br>4.2 mL NS [89]<br><br>500 mg:<br>20 mL NS [89]<br><br>1000 mg:<br>40 mL NS [89] | 25 mg/mL [89] | 12 h F [10,89] | 100 mL NS [89] | 24 h F [89] | - do **NOT** mix with calcium containing solution<br>(e.g., LR) [89] |
| **Pentostatin**<br>10 mg<br>(Hospira/Pfizer)<br>(F)<br>no preservative [90] | 5 mL SWI [90] | 2 mg/mL [90] | 8 h RT [90] | 0.18-0.33 mg/mL [90]<br><br>25-50 mL<br>**NS**, D5W [90] | 8 h RT [90] | |
| **PERTuzumab**<br>420 mg/14 mL<br>(Roche)<br>(F)(PFL)<br>no preservative [91] | N/A | 30 mg/mL [91]<br><br>do NOT shake [91] | discard unused portion [45,91] | 250 mL<br>**NS** only [91]<br><br>mix by gentle inversion to avoid foaming [91]<br><br>do NOT use dextrose containing solutions [91] | 24 h **F**, RT [91] | |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **PERTuzumab-trastuzumab**<br>1200 mg-600 mg/15 mL<br>600 mg-600 mg/10 mL<br>(Roche)<br>(F)(PFL)<br>do not shake<br>no preservative [92] | N/A | **1200 mg -600 mg** [92]**:**<br>80 mg/mL pertuzumab<br>and<br>40 mg/mL trastuzumab<br><br>**600 mg -600 mg** [92]:<br>60 mg/mL pertuzumab<br>and<br>60 mg/mL trastuzumab | discard unused portion [92] | SC syringe [92] | 10 d F, 24 h RT [10,92] | - do not shake [92]<br>- contains recombinant human hyaluronidase [92] |
| **Plerixafor**<br>24 mg/1.2 mL<br>(sanofi-aventis)<br>(RT)<br>no preservative [93] | N/A | 20 mg/mL [93] | discard unused portion [93] | SC syringe [93] | 48 h RT [74,94] | |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Polatuzumab vedotin**<br>30 mg<br>140 mg<br>(Hoffman-La Roche)<br>(F)(PFL)<br>do not shake<br>no preservative [95] | 30 mg:<br>1.8 mL SWI [95]<br><br>140 mg:<br>7.2 mL SWI [95]<br><br>direct diluent against side of vial during reconstitution [95]<br><br>swirl gently to mix [95] | 20 mg/mL [95]<br><br>(PFL) | 12 h F, RT [10,95] | 0.72-2.7 mg/mL<br>**NS**, D5W, ½NS [95]<br><br>(dilute to a minimum volume of 50 mL) [95]<br><br>gently invert bag to mix [95] | in NS:<br>72 h **F**, 4 h RT [95]<br><br>in D5W or ½NS:<br>72 h **F**, 8 h RT [95] | - do NOT shake [95]<br>- administer with 0.2 micron in-line filter [95]<br>-discard if discolouration or visible particulates are present [95] |
| **Pralatrexate**<br>20 mg/1 mL<br>40 mg/2 mL<br>(Servier)<br>(F)(PFL)<br>no preservative [96] | N/A | 20 mg/mL [96] | discard unused portion [2] | syringe [96] | 24 h **F**, RT [97]<br><br>**(PFL) [97] | - do NOT dilute [96] |
| **Raltitrexed**<br>2 mg<br>(Pfizer)<br>(**F**,RT)(PFL)<br>no preservative [98] | 4 mL SWI [98] | 0.5 mg/mL [98] | 12 h **F**, RT [10,98] | 50-250 mL<br>**NS**, D5W [98] | complete administration within 24 h **F**, RT [98] | |




Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Ramucirumab**<br>100 mg/10 mL<br>500 mg/50 mL<br>(Eli Lilly)<br>(F)(PFL)<br>(do not shake)<br>no preservative [99] | N/A | 10 mg/mL [99] | discard unused portion [99] | 0.4–4 mg/mL<br>**NS** [99,100]<br><br>250-500 mL†<br><br>gently invert to mix [99]<br><br>do NOT shake [99]<br><br>do NOT use dextrose containing solutions [99] | 24 h F, 4 h RT [99] | - administer with 0.2 micron in-line filter [99] |
| **Retifanlimab**<br>500 mg/20 mL<br>(Incyte)<br>(F)(PFL)<br>do not shake<br>no preservative [101]<br>(SAP) | N/A | 25 mg/mL [101] | discard unused portion [101] | 1.4-10 mg/mL<br>**NS**, D5W [101]<br><br>50 mL*<br><br>mix by gentle inversion [101];<br>do not shake [101] | complete administration within **24 h F** or 8 h RT [101]<br><br>if refrigerated, bring to RT prior to use and complete administration within 4 h RT after removing from fridge [101]<br><br>**(PFL) [101] | - discard if cloudy, discoloured, or contains particulates [101]<br>- administer using 0.2 micron filter [101] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **riTUXimab (RITUXAN®)**<br>100 mg/10 mL<br>500 mg/50 mL<br>(Roche)<br>(F)(PFL)<br>no preservative [102] | N/A | 10 mg/mL [102] | discard unused portion [102] | 1-4 mg/mL<br>**NS**, D5W [102]<br><br>250-500 mL† | **NS:**<br>10 d F<br>plus an additional<br>24 h RT [10,102]<br><br>**D5W:**<br>24 h F<br>plus an additional<br>12 h RT [102] | |
| **riTUXimab**<br>**intravitreal injection**<br>**(RITUXAN®)**<br>100 mg/10 mL<br>(Roche)<br>(F)(PFL)<br>no preservative [102] | N/A | 10 mg/mL [102] | discard unused portion [102] | syringe<br>for<br>intravitreal use | use within<br>4 h<br>of initial puncture [10] | |
| **riTUXimab**<br>**subcutaneous**<br>**(RITUXAN® SC)**<br>1400 mg/11.7 mL<br>1600 mg/13.4 mL<br>(Roche)<br>(F)(PFL)<br>no preservative [103] | N/A | 120 mg/mL [103] | discard unused portion [103] | SC syringe [103] | 48 h F<br>plus 8 h RT [103] | - contains hyaluronidase [103]<br>- formulations are NOT interchangeable [103] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **riTUXimab**<br>(**RIXIMYO®**)<br>100 mg/10 mL<br>500 mg/50 mL<br>(Sandoz)<br>(F)(PFL)<br>(do NOT shake)<br>no preservative [104] | N/A | 10 mg/mL [104] | discard unused portion [104] | 1-4 mg/mL<br>**NS**, D5W [104]<br><br>250-500 mL†<br><br>gently invert to mix | **NS**:<br>10 d F<br>plus an additional<br>24 h RT [10,104]<br><br>**D5W**:<br>24 h F<br>plus an additional<br>12 h RT [104] | |
| **riTUXimab**<br>**<u>intravitreal injection</u>**<br>(**RIXIMYO®**)<br>100 mg/10 mL<br>(Sandoz)<br>(F)(PFL)<br>(do NOT shake)<br>no preservative [104] | N/A | 10 mg/mL [104] | discard unused portion [104] | syringe<br>for<br>intravitreal use | use within<br>4 h<br>of initial puncture [10] | |
| **riTUXimab**<br>(**RUXIENCE®**)<br>100 mg/10 mL<br>500 mg/50 mL<br>(Pfizer)<br>(F)(PFL)<br>no preservative [105] | N/A | 10 mg/mL [105] | discard unused portion [105] | 1-4 mg/mL<br>**NS**, D5W [105]<br><br>250-500 mL†<br><br>gently invert to mix | 24 h F<br>plus an additional<br>24 h RT [105] | |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **riTUXimab**<br>**intravitreal injection**<br>(**RUXIENCE®**)<br>100 mg/10 mL<br>500 mg/50 mL<br>(Pfizer)<br>(F)(PFL)<br>no preservative [105] | N/A | 10 mg/mL [105] | discard unused portion [105] | syringe<br>for<br>intravitreal use | use within<br>4 h<br>of initial puncture [10] | |
| **riTUXimab**<br>(**TRUXIMA®**)<br>100 mg/10 mL<br>500 mg/50 mL<br>(Teva/Celltrion)<br>(F)(PFL)<br>no preservative [106] | N/A | 10 mg/mL [106] | discard unused portion [106] | 1-4 mg/mL<br>**NS**, D5W [106]<br><br>250-500 mL†<br><br>gently invert to mix | 24 h F<br>plus an additional<br>12 h RT [106] | |
| **riTUXimab**<br>**intravitreal injection**<br>(**TRUXIMA®**)<br>100 mg/10 mL<br>500 mg/50 mL<br>(Teva/Celltrion)<br>(F)(PFL)<br>no preservative [106] | N/A | 10 mg/mL [106] | discard unused portion [106] | syringe<br>for<br>intravitreal use | use within<br>4 h<br>of initial puncture [10] | |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **romiDEPsin**<br>10 mg<br>(Celgene Australia)<br>(RT)<br>no preservative [107] | 2.2 mL supplied diluent [107]<br><br>swirl to mix [107] | 5 mg/mL [107] | discard unused portion [107] | 500 mL NS [107] | 24 h F [107] | - vials contain overfill to allow full drug recovery (drug vial contains 11 mg romidepsin; diluent vial has 2.4 mL diluent) [107]<br>- solvent contains 80% propylene glycol and 20% anhydrous ethanol [107] |
| **Sacituzumab govitecan**<br>180 mg<br>(Gilead)<br>(F)(PFL)<br>no preservative [108] | 20 mL NS [108]<br><br>bring vials to RT before reconstitution [108]<br><br>slowly add diluent to vial and gently swirl; allow to dissolve for up to 15 min [108]<br><br>do not shake [108] | 10 mg/mL [108] | use immediately after reconstitution to prepare infusion solution [108]<br><br>discard unused portion [108] | 1.1-3.4 mg/mL NS [108]<br><br>100-1000 mL† <br><br>slowly inject solution to bag to minimize foaming; do not shake [108] | 24 h F [108], plus an additional 8 h RT including infusion time [108]<br><br>**(PFL) [108] | - do not shake [108]<br>- protect container from light during administration [108]<br>- vials contain overfill (~20 mg per vial) [109] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Siltuximab**<br>100 mg<br>400 mg<br>(Recordati/EUSA)<br>(F)(PFL)<br>no preservative[110,111] | 100 mg:<br>5.2 mL SWI[110]<br><br>400 mg:<br>20 mL SWI[110]<br><br>bring vial to RT prior to use (~30 min)[110]<br><br>gently swirl, do NOT shake[110] | 20 mg/mL[110] | 2 h RT[110] | 250 mL D5W[110]<br><br>dilute to final volume by withdrawing volume from bag equal to volume of drug to be added[110]<br><br>gently mix[110] | complete administration within 6 h RT[110] | - administer with 0.2 micron in-line filter[110]<br>- do not use if visibly opaque, discoloured, or contains particles[110] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Sirolimus, nanoparticle, albumin-bound (NAB)**<br>100 mg<br>(Aadi)<br>(F)(PFL)<br>no preservative [112]<br>(SAP) | 20 mL NS [112]<br><br>slowly direct diluent against side of vial (over ≥1 min) [112]<br><br>let stand for ≥5 min to wet powder [112]<br><br>gently swirl or invert for ≥2 min to avoid foaming [112]<br><br>if foaming/clumping occurs, let stand until foam subsides (≥15 min) [112] | 5 mg/mL [112] | 4 h F [113,114]<br><br>**(PFL) [112] | undiluted in empty PVC or non-PVC infusion bag [112] | 9 h F, followed by max 4 h RT [112]<br><br>**(PFL) [112] | - each vial contains ~800-900 mg human albumin [112,115]<br>- to prevent foaming, do NOT inject NS directly onto the powder [112]<br>- if powder is visible after reconstitution, gently invert to resuspend powder [112]<br>- to prevent administration of proteinaceous strands, administer with 15 micron filter ONLY [112] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Streptozocin**<br>1g<br>(Keocyt)<br>(F)(PFL)<br>no preservative [116-119]<br>(SAP) | 9.5mL **NS,**<br>SWI, D5W [116-119] | 100 mg/mL [116-119] | 12 h F [10,117-119] | syringe [117-119] | 48 h F [10,117-119] | |
| | | | | 100-500 mL<br>**NS**, D5W, SWI [116-119] | 24 h F [117-119] | |
| **Tarlatamab**<br>1 mg<br>(Amgen)<br>(F)(PFL)<br>no preservative [120] | 1.3 mL SWI<br><br>do NOT use supplied IV solution stabilizer to reconstitute vials [120]<br><br>direct diluent against side of vial [120]<br><br>gently swirl to mix; do not shake [120] | 0.9 mg/mL [120] | discard unused portion [10] | 250 mL NS [120]<br><br>add 13 mL supplied IV solution stabilizer to NS bag and gently mix to avoid foaming; do not shake [120]<br><br>add 1.1 mL reconstituted drug to IV bag **following** addition of IV solution stabilizer [120]<br><br>gently mix by inverting bag; do not shake [120] | complete administration within 7 d F, 8 h RT [120] | - **CAUTION**: two vial sizes are available; final vial concentrations are different after reconstitution<br>- due to low extractable volume, use filtered venting needle (e.g., Chemo-Vent®) in place of CSTD for compounding [121]<br>-vials contain overfill to allow full drug recovery [120]<br>- discard if cloudy or has particulates [120] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Tarlatamab**<br>10 mg<br>(Amgen)<br>(F)(PFL)<br>no preservative [120] | 4.4 mL SWI [120]<br><br>do NOT use supplied IV solution stabilizer to reconstitute vials [120]<br><br>direct diluent against side of vial [120]<br><br>gently swirl to mix; do not shake [120] | 2.4 mg/mL [120] | discard unused portion [10] | 250 mL NS [120]<br><br>add 13 mL supplied IV solution stabilizer to NS bag and gently mix to avoid foaming; do not shake [120]<br><br>add 4.2 mL reconstituted drug to IV bag **following** addition of IV solution stabilizer [120]<br><br>gently mix by inverting bag; do not shake [120] | complete administration within 7 d F, 8 h RT [120] | - **CAUTION**: two vial sizes are available; final vial concentrations are different after reconstitution<br>- due to low extractable volume, use filtered venting needle (e.g., Chemo-Vent®) in place of CSTD for compounding [121]<br>-vials contain overfill to allow full drug recovery [120]<br>- discard if cloudy or has particulates [120] |

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Tebentafusp**<br>100 mcg/0.5 mL<br>(Immunocore/Medison)<br>(F)(PFL)<br>do not shake<br>no preservative [122] | N/A | 200 mcg/mL [122] | discard unused portion [122] | 100 mL NS [122]<br><br>Step 1:<br>add calculated volume of human albumin 5% to provide 225-275 mcg/mL final concentration [122]<br><br>to mix:<br>invert the bag and gently rotate ≥5 times;<br>do NOT shake bag (repeat x3) [122]<br><br>Step 2:<br>add calculated volume of drug [122]<br><br>to mix:<br>invert the bag and gently rotate ≥5 times;<br>do NOT shake bag (repeat x3) [122] | complete administration within 24 h F, 4 h RT [122]<br><br>bring to RT prior to administration [122] | - do not use CSTD or filters during **preparation** [122]; use filtered venting needle (e.g., Chemo-Vent®) for preparation<br>- CSTD can be used for administration [123]<br>- administer using 0.2 micron in-line filter [122]<br>- once the bag has been removed from fridge, it must remain at RT [122] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Teclistamab**<br>30 mg/3 mL<br>153 mg/1.7 mL<br>(Janssen)<br>(F)(PFL)<br>do not shake<br>no preservative [124] | N/A | 30 mg [124]:<br>10 mg/mL<br><br>(use for 2.1-52.9 mg doses)*<br><br>153 mg [124]:<br>90 mg/mL<br><br>(use for 53-375 mg doses)*<br><br>bring to RT before use (~15 min) [124]<br><br>swirl gently for 10 sec to mix; do NOT shake [124] | discard unused portion [124] | SC syringe [124]<br><br>if drug volume >2 mL, divide volume into separate syringes for administration [124] | 20 h **F**, RT [124]<br><br>if stored in fridge, bring to RT prior to administration [124] | - **CAUTION**: two concentrations are available [124]<br>- do not use CSTD for volumes less than 1 mL [125]; use filtered venting needle (e.g., Chemo-Vent®) for preparation [126] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Temsirolimus**<br>30 mg/1.2 mL<br>(Pfizer/Wyeth)<br>(F)(PFL) [127]<br>no preservative [128] | 1.8 mL supplied diluent [127] | 10 mg/mL [127] | 12 h RT [10,127]<br><br>**(PFL) [127] | 250 mL NS [127]<br><br>record time of dilution [127] | complete administration within 6 h [127]<br><br>mix by gentle inversion to avoid foaming [127] | - use non-DEHP bag and tubing<br>- administer with 0.2 micron in-line filter [127] |
| **Teniposide**<br>50 mg/5 mL<br>(BMS)<br>(RT)<br>preservative [129] | N/A | 10 mg/mL [129] | discard unused portion | 0.1-1 mg/mL<br>**NS,** D5W [129]<br><br>50–500 mL* | 0.1-0.4 mg/mL:<br>24 h RT [129]<br><br>1 mg/mL:<br>complete administration within<br>4 h RT<br>of preparation [129,130] | - do not refrigerate<br>- use non-DEHP bag and tubing [129]<br>- do not use if precipitates [129,130]<br>- contains DMA***<br>- excessive agitation may cause precipitation [129] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Thiotepa**<br>15 mg<br>100 mg<br>(Hikma)<br>(F, PFL)<br>no preservative [131] | **15 mg** [131]**:**<br>1.5 mL SWI<br><br>**100 mg** [131]**:**<br>10 mL SWI<br><br>to remove haze, filter through 0.22 micron filter disc after reconstitution [132]<br><br>record time of reconstitution | 10 mg/mL [131] | 8 h F [131] | 0.5-1 mg/mL NS [131]<br><br>≤500 mg [131]:<br>500 mL<br><br>>500 mg [131]:<br>1000 mL<br><br>reconstituted solution is hypotonic and must be further diluted with NS prior to use [131] | 24 h F, 4 h RT [131] | - discard if precipitates are present [131]<br>- reconstituted solution may be used if opalescent [131]<br>- administer with 0.2 micron in-line filter [131]<br>- use non-PVC bag and administration set [131] |

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Thiotepa**<br>**IT injection**<br>15 mg<br>100mg<br>(Hikma)<br>(F, PFL)<br>no preservative [131] | **15 mg** [131]**:**<br>1.5 mL SWI<br><br>**100 mg** [131]**:**<br>10 mL SWI<br><br>diluents containing preservatives should **NOT** be used for intrathecal administration [25]<br><br>to remove haze, filter through 0.22 micron filter disc after reconstitution [132]<br><br>record time of reconstitution | 10 mg/mL [131] | 8 h F [131] | IT syringe<br><br>qs to 6 mL with preservative free NS [133]<br><br>diluents containing preservatives should **NOT** be used for intrathecal administration [25] | use within 4 h of initial reconstitution [10] | - auxiliary info [134]: IT<br>- label to include route in full (i.e., INTRATHECAL injection) attached to both syringe and outer ziplock bag [134]<br>- discard if precipitates are present [131]<br>- reconstituted solution may be used if opalescent [131] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Thiotepa**<br>15 mg<br>100 mg<br>(SteriMax)<br>(F, PFL)<br>no preservative [135] | **15 mg** [135]**:**<br>1.5 mL SWI<br><br>**100 mg** [135]**:**<br>10 mL SWI<br><br>to remove haze, filter through 0.22 micron filter disc after reconstitution [132]<br><br>record time of reconstitution | 10 mg/mL [135] | 8 h F [135] | 0.5-1 mg/mL NS [135]<br><br>≤500 mg [135]:<br>500 mL<br><br>>500 mg [135]:<br>1000 mL<br><br>reconstituted solution is hypotonic and must be further diluted with NS prior to use [135] | 24 h F, 4 h RT [135] | - discard if precipitates are present [135]<br>- reconstituted solution may be used if opalescent [135]<br>- administer with 0.2 micron in-line filter [135]<br>- use non-PVC bag and administration set [135] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Thiotepa**<br>**<u>IT injection</u>**<br>15 mg<br>100mg<br>(SteriMax)<br>(F, PFL)<br>no preservative [135] | **15 mg** [135]**:**<br>1.5 mL SWI<br><br>**100 mg** [135]**:**<br>10 mL SWI<br><br>diluents containing preservatives should **NOT** be used for intrathecal administration [25]<br><br>to remove haze, filter through 0.22 micron filter disc after reconstitution [132]<br><br>record time of reconstitution | 10 mg/mL [135] | 8 h F [135] | IT syringe<br><br>qs to 6 mL with preservative free NS [133]<br><br>diluents containing preservatives should **NOT** be used for intrathecal administration [25] | use within 4 h of initial reconstitution [10] | - auxiliary info [134]: IT<br>- label to include route in full (i.e., INTRATHECAL injection) attached to both syringe and outer ziplock bag [134]<br>- discard if precipitates are present [135]<br>- reconstituted solution may be used if opalescent [135] |
| **Thyrotropin alfa**<br>1.1 mg<br>(Genzyme)<br>(F)(PFL)<br>no preservative [136] | 1.2 mL SWI [136]<br><br>swirl gently to mix [136]<br><br>do NOT shake [136] | 0.9 mg/mL [136] | 12 h F [10,136] | syringe [136] | 24 h F [10,136] | - do not use if particulates are present [136] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Tislelizumab**<br>100 mg/10 mL<br>(BeiGene)<br>(F)(PFL)<br>(do not shake)<br>no preservative [137]<br>(SAP) | N/A | 10 mg/mL [137] | discard unused portion [137] | 2-5 mg/mL NS [137]<br><br>50 mL*<br><br>mix by gentle inversion; do not shake [137] | complete administration within 20 h F, 4 h RT (max 24 h from preparation) [137]<br><br>bring to RT prior to administration [137] | - discard if has visible particulates, or is discoloured or cloudy [137]<br>- administer with 0.2 micron in-line filter [137] |
| **Tocilizumab**<br>80 mg/4 mL<br>200 mg/10 mL<br>400 mg/20 mL<br>(Roche)<br>(F)(PFL)<br>no preservative [138] | N/A | 20 mg/mL [138] | discard unused portion [138] | 100 mL NS [138]<br><br>dilute to final volume by withdrawing volume from bag equal to volume of drug to be added [138]<br><br>gently invert to mix [138] | complete administration within 24 h **F**, RT [138]<br><br>bring to RT prior to administration [138] | - to prevent foaming: slowly add drug to infusion bag and gently invert bag to mix [138] |
| **Topotecan**<br>4 mg/4 mL<br>(Accord)<br>(RT)(PFL)<br>no preservative [139] | N/A | 1 mg/mL [139] | 12 h **F**, RT [10,139] | 0.025-0.5 mg/mL **NS**, D5W [139]<br><br>25-50 mL† | 10 d F, 4 d RT [10,139] | |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Topotecan**<br>**IT injection**<br>4 mg/4 mL<br>(Accord)<br>(RT)(PFL)<br>no preservative [139] | N/A | 1 mg/mL [139] | use within<br>4 h<br>of initial puncture<br>[10] | IT syringe<br><br>qs to 10 mL with preservative free NS [26,140,141]<br><br>diluents containing preservatives should **NOT** be used for intrathecal administration [25] | use within<br>4 h<br>of initial puncture [10] | - auxiliary info [10]: IT<br>- label to include route in full (i.e., INTRATHECAL injection) attached to both syringe and outer ziplock bag [26] |
| **Topotecan**<br>4 mg/4 mL<br>(Pfizer/Hospira)<br>(F)(PFL)<br>no preservative [142] | N/A | 1 mg/mL [142] | discard unused portion [142] | 0.02-0.5 mg/mL<br>**NS**, D5W [142]<br><br>25-50 mL† | 24 h **F**, RT [142] | |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Topotecan**<br>**IT injection**<br>4 mg/4 mL<br>(Pfizer/Hospira)<br>(F)(PFL)<br>no preservative [142] | N/A | 1 mg/mL [142] | use within<br>4 h<br>of initial puncture<br>[10] | IT syringe<br><br>qs to 10 mL with preservative free NS [26,140,141]<br><br>diluents containing preservatives should **NOT** be used for intrathecal administration [25] | use within<br>4 h<br>of initial puncture [10] | - auxiliary info [10]: IT<br>- label to include route in full (i.e., INTRATHECAL injection) attached to both syringe and outer ziplock bag [26] |
| **Topotecan**<br>4 mg/4 mL<br>(Sandoz)<br>(F)(PFL)<br>no preservative [143] | N/A | 1 mg/mL [143] | discard unused portion [143] | 0.02-0.5 mg/mL<br>**NS**, D5W [143]<br><br>25-50 mL† | 24 h F [143]<br><br>**(PFL) [143] | |

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Topotecan**<br>**IT injection**<br>4 mg/4 mL<br>(Sandoz)<br>(F)(PFL)<br>no preservative [143] | N/A | 1 mg/mL [143] | use within<br>4 h<br>of initial puncture<br>[10] | IT syringe<br><br>qs to 10 mL with preservative free NS [26,140,141]<br><br>diluents containing preservatives should **NOT** be used for intrathecal administration [25] | use within<br>4 h<br>of initial puncture [10]<br><br>**(PFL) [143] | - auxiliary info [10]: IT<br>- label to include route in full (i.e., INTRATHECAL injection) attached to both syringe and outer ziplock bag [26] |
| **Trastuzumab**<br>**(HERCEPTIN®)**<br>440 mg<br>(Roche)<br>(F)<br>no preservative [144] | 20 mL supplied<br>BWI [144]<br><br>swirl vial gently; allow to stand undisturbed for 5 min [144] | 21 mg/mL [144] | 28 d F [144] | 250 mL<br>**NS** only [144]<br><br>do NOT use dextrose containing solutions [144] | 24 h **F**, RT [144] | - do NOT shake [144] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Trastuzumab (HERZUMA®)**<br>150 mg<br>440 mg<br>(Teva/Celltrion)<br>(F)<br>no preservative [145] | 150 mg:<br>7.2 mL SWI [145] | 21 mg/mL [145] | discard unused portion [145] | 250 mL<br>**NS** only [145]<br><br>do NOT use dextrose containing solutions [145] | 24 h **F**, RT [145] | - do NOT shake [145]<br>- supplied BWI contains benzyl alcohol [145] |
| | 440 mg:<br>20 mL supplied BWI [145] | | 28 d F [145] | | | |
| | swirl vial gently; allow to stand undisturbed for 5 min [145] | | | | | |
| **Trastuzumab (OGIVRI®)**<br>150 mg<br>440 mg<br>(BGP)<br>(F)<br>no preservative [146] | 150 mg:<br>7.2 mL SWI [146] | 21 mg/mL [146] | discard unused portion [146] | 250 mL<br>**NS** only [146]<br><br>do NOT use dextrose containing solutions [146] | 24 h **F**, RT [146] | - do NOT shake [146]<br>- supplied BWI contains benzyl alcohol [146] |
| | 440 mg:<br>20 mL supplied BWI [146] | | 28 d F [146] | | | |
| | swirl vial gently; allow to stand undisturbed for 5 min [146] | | | | | |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Trastuzumab (TRAZIMERA®)**<br>150 mg<br>440 mg<br>(Pfizer)<br>(F)<br>no preservative [147] | 150 mg:<br>7.2 mL SWI [147] | 21 mg/mL [147] | discard unused portion [147] | 250 mL<br>**NS** only [147]<br><br>do NOT use dextrose containing solutions [147] | 24 h **F**, RT [147] | - do NOT shake [147]<br>- supplied BWI contains benzyl alcohol [147] |
| | 440 mg:<br>20 mL supplied BWI [147] | | 28 d F [147] | | | |
| | swirl vial gently; allow to stand undisturbed for 5 min [147] | | | | | |
| **Trastuzumab deruxtecan (ENHERTU®)**<br>100 mg<br>(AstraZeneca)<br>(F)(PFL)<br>no preservative [148] | 5 mL SWI [148]<br><br>swirl gently until completely dissolved [148]<br><br>do NOT shake [148] | 20 mg/mL [148] | 12 h F [10,148]<br><br>**(PFL) [148] | 100 mL<br>**D5W only** [148]<br><br>gently invert to mix [148]<br><br>do NOT shake [148]<br><br>do NOT use sodium chloride solution [148] | complete administration within 24 h F, 4 h RT [148]<br><br>**(PFL) [148] | - do not use if reconstituted solution contains visible particulates or is cloudy or discoloured [148]<br>- protect container from light during administration [149]<br>- administer with 0.2 micron in-line filter [148]<br>- if stored in fridge, bring bag to RT prior to use [148] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Trastuzumab emtansine (KADCYLA®)**<br>100 mg<br>160 mg<br>(Roche)<br>(F)(PFL)<br>no preservative [150] | 100 mg:<br>5 mL SWI [150]<br><br>160 mg:<br>8 mL SWI [150]<br><br>swirl gently until completely dissolved<br><br>do NOT shake [150] | 20 mg/mL [150] | 12 h **F** [10,151] | 250 mL<br>**NS** or ½NS only [150]<br><br>do NOT shake [150]<br><br>do NOT use dextrose containing solutions [150] | 24 h F [150] | - do not use if reconstituted solution contains visible particulates or is cloudy or discolored [150]<br>- D5W causes aggregation of the protein [150]<br>- for infusions prepared in NS: administer with 0.2 micron in-line filter or 0.22 micron polyethersulfane (PES) filter [150]<br>- for infusions prepared in ½NS: filter is optional for administration [150] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Tremelimumab**<br>25 mg/1.25 mL<br>300 mg/15 mL<br>(AstraZeneca)<br>(F)(PFL)<br>(do not shake)<br>no preservative [152] | N/A | 20 mg/mL [152] | discard unused portion [152] | 0.1-10 mg/mL **NS,** D5W [152]<br><br>50 mL*<br><br>mix by gentle inversion;<br>do NOT shake [152] | 24 h **F**, RT [152] | - administer with 0.2 micron in-line filter [152]<br>- discard if visible particles are present [152] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Treosulfan**<br>1 g<br>5 g<br>(Medexus)<br>(RT)<br>no preservative [153] | 1 g [153]:<br>20 mL NS, D5W, SWI, ½NS<br><br>5 g [153]:<br>100 mL NS, D5W, SWI, ½NS<br><br>**pre-heat** diluent to 25-30°C (max) [154]<br><br>**shake vial** to loosen powder before adding the warmed diluent [155]<br><br>vigorous shaking may be required [155]; prolonged standing time may improve solubility [153] | 50 mg/mL [153] | 12 h RT [10,153] | undiluted<br>in empty infusion bag [153,154] | 3 d RT [153] | - do NOT refrigerate as may precipitate [153] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Treosulfan**<br>1 g<br>5 g<br>(medac)<br>(RT)<br>no preservative [156,157]<br>(SAP) | 1 g [156,157]:<br>20 mL SWI, ½NS<br><br>5 g [156,157]:<br>100 mL SWI, ½NS<br><br>pre-heat diluent to 25-30°C (max) [156,157]<br><br>shake vial carefully to loosen powder before adding the warmed diluent [156,157]<br><br>gently shake while adding diluent [156,157]<br><br>(takes ~2 min to reconstititute) [156,157] | 50 mg/mL [156,157] | 12 h RT [10,156,158] | undiluted [159]<br><br>or<br><br>dilute with **NS** or D5W in empty infusion bag to final concentration of 20 mg/mL [158] | 4 d RT [156,158] | - compatible with polytetrafluoroethylene filters [160]<br>- may sometimes require vigorous shaking to reconstitute [156,157]<br>- do NOT refrigerate as may cause precipitation [156,157] |
| **vinBLAStine**<br>10 mg/10 mL<br>(Pfizer)<br>(F)(PFL)<br>no preservative [161] | N/A | 1 mg/mL [161] | discard unused portion [2,161] | 25-50 mL<br>**NS**, D5W [162] | use within 4 h of initial vial puncture [2,161] | - auxiliary info: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES [163,164] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **vinBLAStine**<br>10 mg/10 mL<br>(Teva)<br>(F)(PFL)<br>no preservative [165] | N/A | 1 mg/mL [165] | discard unused portion [2,165] | 25-50 mL<br>**NS**, D5W [162] | use within<br>4 h<br>of initial<br>vial puncture [2,165] | - auxiliary info: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES [163,164] |
| **vinCRIStine**<br>2 mg/2 mL<br>5 mg/5 mL<br>(Pfizer/Hospira)<br>(F)(PFL)<br>no preservative [166] | N/A | 1 mg/mL [166] | 8 h F, RT [166] | 0.01-0.1 mg/mL<br>**NS**, D5W [166]<br><br>50 mL† | 24 h F, RT [166]<br><br>**(PFL) [166] | - auxiliary info: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES [163,164]<br>- for LYEPOCHR protocol, see entry for EPOCHR (3-in-1 solution containing either etoposide or etoposide phosphate AND DOXOrubicin and vinCRIStine) |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **vinCRIStine**<br>1 mg/1 mL<br>2 mg/2 mL<br>5 mg/5 mL<br>(Teva)<br>(F)(PFL)<br>no preservtive [167] | N/A | 1 mg/mL [167] | 8 h **F**, RT [167] | 0.01-0.1 mg/mL<br>**NS**, D5W [167]<br><br>50 mL† | 24 h F, RT [167] | - auxiliary info: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES [163,164]<br>- for LYEPOCHR protocol, see entry for EPOCHR (3-in-1 solution containing either etoposide or etoposide phosphate AND DOXOrubicin and vinCRIStine) |
| **Vinorelbine**<br>10 mg/1 mL<br>50 mg/5mL<br>(Fresenius Kabi)<br>(F)(PFL)<br>no preservative [168] | N/A | 10 mg/mL [168] | discard unused portion [168] | 0.5-2.0 mg/mL<br>**NS**, D5W, ½NS, D5-½NS, LR, Ringer's [168]<br><br>50 mL† | 24 h **F**, RT [168] | - auxiliary info: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES [163,164] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Vinorelbine**<br>10 mg/1 mL<br>50 mg/5 mL<br>(GMP)<br>(F)(PFL)<br>no preservative [169] | N/A | 10 mg/mL [169] | discard unused portion [2] | 0.5-2.0 mg/mL<br>**NS**, D5W, ½NS, D5-½NS, LR, Ringer's [169]<br><br>50 mL† | 24 h **F**, RT [169] | - auxiliary info: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES [163,164] |
| **Vinorelbine**<br>10 mg/1 mL<br>50 mg/5 mL<br>(Teva)<br>(F)(PFL)<br>no preservative [170] | N/A | 10 mg/mL [170] | discard unused portion [170] | 0.5–2.0 mg/mL<br>**NS**, D5W, ½NS, D5-½NS, LR, Ringer's [170]<br><br>50 mL† | 24 h **F**, RT [170] | - auxiliary info: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES [163,164] |
| **Zoledronic acid**<br>4 mg/5 mL<br>(Dr Reddy's)<br>(RT)<br>no preservative [171] | N/A | 0.8 mg/mL [171] | discard unused portion [171] | 100 mL<br>**NS**, D5W [171] | complete infusion within 24 h of preparation [171]<br><br>**refrigerate** diluted product if not used immediately after preparation; bring to RT prior to use [171] | - do **NOT** mix with calcium containing solutions (e.g., LR) [171] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Zoledronic acid**<br>4 mg/5 mL<br>(Marcan)<br>(RT)<br>no preservative [172] | N/A | 0.8 mg/mL [172] | discard unused portion [172] | 100 mL<br>**NS**, D5W [172] | complete infusion within 24 h of preparation [172]<br><br>**refrigerate** diluted product if not used immediately after preparation; bring to RT prior to use [172] | - do **NOT** mix with calcium containing solutions (e.g., LR) [172] |
| **Zoledronic acid**<br>4 mg/5 mL<br>(MDA)<br>(RT)<br>no preservative [173] | N/A | 0.8 mg/mL [173] | discard unused portion [173] | 100 mL<br>**NS**, D5W [173] | complete infusion within 24 h of preparation [173]<br><br>**refrigerate** diluted product if not used immediately after preparation; bring to RT prior to use [173] | - do **NOT** mix with calcium containing solutions (e.g., LR) [173] |



Activation Date: 2 March 2006
Revised Date: 12 March 2025

| BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART | | | | | | |
|---|---|---|---|---|---|---|
| **DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)** | **Reconstitute With:** | **To Give:** | **Vial Stability** | **Product (for IV bag size selection, see Notes†)** | **Product Stability** | **Special Precautions/Notes** |
| **Zoledronic acid**<br>(ZOMETA)<br>4 mg/ 5 mL<br>(Novartis)<br>(RT)<br>no preservative [174] | N/A | 0.8 mg/mL [174] | discard unused portion [45] | 100 mL<br>**NS,** D5W [174] | complete infusion within 24 h of preparation [174]<br><br>**refrigerate** diluted product if not used immediately after preparation; bring to RT prior to use [174] | - do NOT mix with calcium containing solutions (e.g., LR) [174] |
| **Zoledronic acid**<br>4 mg/5 mL<br>(Sandoz)<br>(RT)<br>no preservative [175] | N/A | 0.8 mg/mL [175] | discard unused portion [175] | 100 ml<br>**NS**, D5W [175] | complete infusion within 24 h of preparation [175]<br><br>**refrigerate** diluted product if not used immediately after preparation; bring to RT prior to use [175] | - do NOT mix with calcium containing solutions (e.g., LR) [175] |

* Suggested volume based on usual dose range and any concentration range of stability data
† see BC Cancer IV Bag Selection table: standardized bag sizes are provided for select Benefit Drugs with concentration-dependent stability or large drug volume
** Protect from light means minimizing exposure to direct sunlight over a *storage* period. More specific information on protection from light (eg, protecting container and tubing during *administration*) will be indicated in the Special Precautions/Notes column.
*** Contains DMA (N,N dimethylacetamide). Product may be incompatible with closed system transfer devices (CSTD) such as ChemoLock.

**Centres are not to change content locally. All suggestions for change are to be forwarded to the Cancer Drug Manual editor.**



Activation Date: 2 March 2006
Revised Date: 12 March 2025

**Explanatory Notes:**

***Stability data*** assumes products prepared using standard aseptic technique in biological safety cabinet at low risk for contamination according to the classification outlined in USP 797. [176,177]
***Vial stability*:** Stability of solution after first puncture or reconstituted solution.
***Storage temperature:*** If information states same stability with refrigerator and room temperature storage, then fridge stability is bolded as preferred (ie, to minimize growth of micro-organisms).
***Discard unused portion*:** Unused portion from single use vials should be discarded at the end of the day.
***"overfill known"*** is stated if the manufacturer states overfill that is present is within acceptable limits.
***"Complete administration within __"*** is stated if the manufacturer specifies that the infusion must be completed in a specific time frame following preparation, usually including entire time required for preparation (from first puncture), storage, and administration of infusion.
Nomenclature for ***in-line filters*** has been standardized to 0.2 micron filter size. For more information, refer to CDM monograph.

**Abbreviations:**

BWI = bacteriostatic water for injection
CIVI: ambulatory pump = Continuous Intravenous Infusion (e.g., elastomeric infusor)
CSTD = closed system transfer device
D5W = dextrose 5% in water
DMA = N,N dimethylacetamide
F = refrigerate
LR = lactated ringer's solution
non-DEHP = not containing Di(2-ethylhexyl) phthalate (DEHP)
non-PVC = not containing polyvinylchloride (PVC)
NS = normal saline
PFL = protect from light
RT = room temperature
SAP **=** drug is approved for use through the Health Canada Special Access Program
SWI = sterile water for injection

**References:**

1. Generic Medical Partners Inc. Leucovorin calcium injection product monograph. Toronto, Ontario; 6 March, 2020.
2. BC Cancer. Provincial Pharmacy Directive Number II-20: Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer; December 5 , 2018.
3. Pfizer Canada Inc. Leucovorin calcium injection product monograph. Kirkland, Quebec; 21 June, 2018.
4. Teva Canada Limited. Leucovorin calcium injection® product monograph. Toronto, Ontario; 5 May, 2014.
5. Hospira Healthcare Corporation. LEUCOVORIN CALCIUM INJECTION® product monograph. Saint-Laurent, Quebec; 7 June , 2007.
6. Novopharm Limited (Teva). LEUCOVORIN CALCIUM® Injection product information package. Toronto, Ontario; undated,



Activation Date: 2 March 2006
Revised Date: 12 March 2025

7. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 6 January , 2006.
8. Jenny Yeung. Medical Information Specialist, Teva Canada. Personal communication. 12 April, 2017.
9. Jazz Pharmaceuticals Canada Incorporated. ZEPZELCA® product monograph. Mississauga, Ontario; September 29, 2021.
10. BC Cancer. Provincial Pharmacy Directive Number II-20: Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer; May 1 , 2022.
11. Linda Ewing.BD US Market Manager. WW Infusion Disposables. Personal communication. Feb, 2018.
12. Pharma Mar. Lurbinectedin Compassionate Use: Preparation Guide for Infusion - edition 1. Madrid, Spain; April, 2019.
13. Marcan Pharmaceuticals Inc. Melphalan for injection product monograph. Ottawa, ON; July 26, 2019.
14. Taro Pharmaceuticals Inc. Taro-Melphalan product monograph. Brampton, Ontario; April 5, 2019.
15. Baxter Corporation. UROMITEXAN® product monograph. Mississauga, Ontario; 6 August, 2013.
16. Mona Ghobros BPharm MSc. Medical Information, Baxter Corporation. Personal communication. 29 November, 2018.
17. Trissel's® 2 Clinical Pharmaceutics Database (database on the Internet). Mesna. Lexi-Comp Inc.; created by Lawrence A. Trissel; Accessed 29 November, 2018. Available at: http://online.lexi.com
18. Fresenius Kabi Canada Ltd. Mesna for injection product monograph. Richmond Hill, Ontario; 21 December, 2017.
19. Fresenius Kabi Canada Ltd. Mesna for injection product monograph. Richmond Hill, Ontario; 30 March, 2015.
20. Accord Healthcare Inc. Methotrexate injection product monograph. Kirkland, Québec; October 30, 2019.
21. Maia M, Farah ME, Belfort RN, et al. Effects of intravitreal triamcinolone acetonide injection with and without preservative. Br J Ophthalmol ; 2007;91(9):1122–1124
22. Mayne Pharma Canada. Methotrexate Product Monograph. Montreal, Quebec; December, 2003.
23. BC Cancer Miscellaneous Origin Tumour Group. (MOIT) BC Cancer Protocol Summary for Solid Tumours using Intrathecal Methotrexate and/or Thiotepa and/or Cytarabine. Vancouver, British Columbia: BC Cancer; September 1 , 2021.
24. BC Cancer Lymphoma Tumour Group. (LYIT) BC Cancer Protocol Summary for Treatment of Lymphoma using Intrathecal Methotrexate and Cytarabine. Vancouver, British Columbia: BC Cancer; April 1 , 2022.
25. Hematology/Oncology Pharmacy Association. HOPA News Clinical Pearls: Intrathecal Chemotherapy: Focus on Drugs, Dosing, and Preparation. 13(4) ed. Chicago, Illinois, USA: Hematology/Oncology Pharmacy Association; 2016.
26. BC Cancer. Systemic Therapy Policy and Procedure III-50: Administration of High Alert Medications by the Intrathecal Route via Lumbar Puncture or Ommaya Reservoir. Vancouver, British Columbia; May 1, 2019.
27. Fresenius Kabi. Methotrexate for injection (lyophilized powder) package insert. Lake Zurich, Illinois, USA; May, 2020.
28. Ng T, Woo S, Badry N, et al. SBAR: Methotrexate Backorder: Concentration Switch Management and Review. Approved by BC Cancer Provincial Pharmacy Professional Practice Committee (P4C). October 24, 2024
29. Pfizer Canada-ULC. Methotrexate injection product monograph. Kirkland, Québec; July 8, 2019.
30. AbbVie Deutschland GmbH & Co. KG. ELAHERE® Summary of Product Characteristics. Ludwigshafen, Germany; April 18th, 2024.
31. Accord Healthcare Inc. Mitomycin product monograph. Kirkland, Quebec; 16 July, 2018.
32. Au JLS, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst ; April 18, 2001;93(8):597–604
33. Jessie LS Au PharmD PhD. Professor, Ohio State University. Personal communication. 14 May, 2007.
34. Myers AL, Zhang Y, Kawedia JD, et al. Solubilization and stability of mitomycin C solutions prepared for intravesical administration. Drugs R D ; 2017;17:297–304
35. Beijnen JH, Van Gijn R, Underberg WJM. Chemical stability of the antitumor drug mitomycin C in solutions for intravesical instillation. Journal of Parenteral Science and Technology ; 1990;44(6):332–335
36. Hikma Canada Limited. Mitomycin for injection product monograph. Mississauga, Ontario; October 12, 2022.
37. Teva Canada Limited. Mitomycin for injection® product monograph. Toronto, Ontario; 30 June, 2017.
38. Fresenius Kabi Canada Ltd. Mitoxantrone injection® product monograph. Richmond Hill, Ontario; September 28, 2016.
39. Pfizer Canada Inc. Mitoxantrone injection product monograph. Kirkland, Quebec; 17 October, 2018.
40. Kyowa Kirin (Distributed by Innomar Strategies). POTELIGEO® product monograph. Oakville, Ontario; July 12, 2023.
41. Sandoz Canada Inc. ATRIANCE® product monograph . Boucherville, Quebec; November 30, 2022.
42. Bristol-Myers Squibb Canada Co. OPDIVO® product monograph. Montreal, Canada; February 28, 2022.
43. Bristol-Myers Squibb Canada. OPDUALAG® product monograph. Montreal, Quebec; 13 September, 2023.
44. Hoffmann-La Roche Ltd. GAZYVA® product monograph. Mississauga, Ontario; 21 December , 2015.

45. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 September , 2007.
46. Anna Sivojelezova MSc. Drug Information Associate, Hoffmann-La Roche Ltd. Personal communication. 24 April, 2015.
47. Omega Laboratories Limited. OCTREOTIDE ACETATE solution product monograph. Montreal, Quebec; January 25, 2022.
48. Novartis Pharmaceuticals Canada Inc. SANDOSTATIN® and SANDOSTATIN® LAR® product monograph. Dorval, Quebec; April 19, 2021.
49. Teva Canada Limited. OCTREOTIDE for injectable suspension Product Monograph. Toronto, Ontario; Aug 30, 2021.
50. Dr. Reddy's Laboratories Canada Inc. Oxaliplatin injection product monograph. Mississauga, Ontario; February 8, 2022.
51. Pfizer Canada Inc. Oxaliplatin injection product monograph. Kirkland, Quebec; 31 May, 2017.
52. Medical Information Pfizer Canada Inc. Personal communication. 6 June, 2017.
53. Sandoz Canada Inc. Oxaliplatin injection product monograph. Boucherville, Quebec; 12 August, 2015.
54. Katryn Vosburg. Drug Information & Pharmacovigilance Specialist, Sandoz Canada Inc. Personal communication. 26 February, 2016.
55. Teva Canada Limited. Teva-Oxaliplatin injection® product monograph. Toronto, Ontario; 11 September, 2015.
56. Accord Healthcare Inc. Paclitaxel Injection. Kirkland, Quebec; September 14, 2020.
57. Mercure C. Stability of 0.1 mg/mL of paclitaxel for injection in sodium chloride (0.9%) solution. St Catharines, Ontario: Biolyse Pharma; 2 February , 2007.
58. Biolyse. PACLITAXEL FOR INJECTION® product monograph. St. Catherines, Ontario; 12 September, 2013.
59. Claude Mercure. Manager BPC. Personal communication. 24 June, 2014.
60. Zeng Z, Lazakovitch E. Study IR 120: Physical and Chemical Stability Study of Paclitaxel for Injection in 0.9 % Sodium Chloride in concentration range 0.012-0.12 mg/mL. Biolyse Pharma ; March, 2010
61. Biolyse. PACLITAXEL FOR INJECTION® product monograph. St. Catherines, Ontario; 2 December , 2005.
62. Xu Q, Trissel LA, Martinez JF. Pharmaceutical Analysis Laboratory, University of Texas M. D. Anderson Cancer Center, Houston 77030. Stability of paclitaxel in 5% dextrose injection or 0.9% sodium chloride injection at 4, 22, or 32 degrees C. Am J Hosp Pharm ; Dec 15, 1994;51(24):3058–60
63. Lisa Tavano. Biolyse Pharma Corporation. Personal communication. 14 May, 2012.
64. Sandoz Canada Inc. Paclitaxel injection USP product monograph . Boucherville, Quebec; October 18, 2021.
65. Bristol-Myers Squibb Canada. ABRAXANE® product monograph. Saint-Laurent, Quebec; March 8, 2024.
66. Aisling Cahill. Drug Safety and Medical Information Specialist. Celgene Inc. Personal communication. April 23, 2015.
67. Panacea Biotec Pharma Limited (distributed by Apotex Inc.). Nanoparticle, albumin-bound paclitaxel product monograph. Toronto, Ontario; November 16, 2021.
68. Panacea Biotec Pharma Limited (R&D L. In-use infusion stability study report for paclitaxel powder for injectable suspension nanoparticle, albumin-bound paclitaxel (100 mg paclitaxel/vial). Toronto, Ontario; October 4, 2023.
69. Pharmaceutical Partners of Canada. Pamidronate Disodium For Injection product monograph. Richmond Hill, Ontario; 18 January , 2010.
70. Mayne Pharma (Canada) Inc. Pamidronate Package Insert. Montreal, Quebec; 2002.
71. Omega Laboratories Ltd. Pamidronate Disodium product monograph. Montreal, Quebec; 06 June , 2005.
72. Pfizer Canada-ULC. Pamidronate disodium for injection product monograph. Kirkland, Quebec; December 11, 2018.
73. Sandoz Canada Inc. Pamidronate injection product monograph. Boucherville, Quebec; 28 February, 2006.
74. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 September , 2007.
75. Amgen Canada. VECTIBIX® product monograph. Mississauga, Ontario; 31 March, 2017.
76. Amgen Inc. VECTIBIX® full prescribing information. Thousand Oaks, California USA; June, 2017.
77. Amgen Canada. VECTIBIX® product monograph. Mississauga, Ontario; 5 March , 2009.
78. Diane Lord. Medical Information Department, Amgen Canada Inc. Personal communication. 19 June, 2009.
79. Servier Canada Inc. ONCASPAR® product monograph. Laval, Quebec; November 22, 2021.
80. Servier Canada Inc. Personal Communication: Availability of US-Labelled ONCASPAR® (pegaspargase injection) for Canadian patients. January 27, 2025.
81. Merck Canada Inc. KEYTRUDA® product monograph. Kirkland, Quebec; 6 December, 2019.
82. Accord Healthcare Inc. Pemetrexed disodium for injection product monograph. Kirkland, Quebec; 12 March, 2015.
83. Accord Healthcare Inc. Pemetrexed solution for injection product monograph. Kirkland, QC; April 26, 2021.
84. Dr. Reddy's Laboratories Limited. Pemetrexed for Injection product monograph . Oakville, Ontario; April 12, 2017.
85. Dr. Reddy's Laboratories Ltd. Pemetrexed for Injection product monograph. Mississauga, Ontario; May 3, 2022.

86. Dr. Reddy's Laboratories Inc. Pemetrexed for injection full prescribing information (package insert). Princeton, NJ, USA; Mar, 2022.
87. Md Aslam. Medical information Associate. Drug information. Dr Reddy's Laboratories. Personal Communication (verbal). December 1, 2022.
88. Eli Lilly and Company. ALIMTA® product monograph. Indianapolis, Indiana, USA; September, 2013.
89. Taro Pharmaceuticals Inc. Pemetrexed disodium for injection product monograph. Brampton, Ontario; 30 August, 2018.
90. Hospira Inc. NIPENT® full prescribing information. Lake Forest, Illinois USA; October, 2019.
91. Hoffmann-La Roche Limited. PERJETA® product monograph. Mississauga, Ontario; April 12, 2013.
92. Hoffmann-La Roche Limited. PHESGO® product monograph. Mississauga, Ontario; January 5, 2022.
93. sanofi-aventis Canada Inc. MOZOBIL® product monograph. Laval, Quebec; 8 October , 2014.
94. Maureen Coughlin BSc Pharm. Solutions in Health Inc. (acting as an authorized agent of sanofi-aventis and ). Personal communication. 24 May, 2017.
95. Hoffman-La Roche Limited. POLIVY® product monograph. Mississauga, Ontario; April 27, 2021.
96. Servier Canada Inc. FOLOTYN® product monograph. Laval, Quebec; 19 October, 2018.
97. Marjolaine Migeon PharmD. Servier Canada Medical Information. Personal communication. 24 September, 2019.
98. Pfizer Canada Inc. TOMUDEX® product monograph. Kirkland, Quebec; 8 August, 2017.
99. Eli Lilly Canada Inc. CYRAMZA® product monograph. Toronto, Ontario; 16 July, 2015.
100. Marilyn Bain BScN. Senior Medical Information Associate, Eli Lilly Canada Inc. Personal communication. 16 January, 2017.
101. Innomar Strategies Inc for Incyte Corporation. ZYNYZ® product monograph (undated). Oakville, Ontario;
102. Hoffmann-La Roche Ltd. RITUXAN® product monograph. Mississauga, Ontario; October 10, 2019.
103. Hoffmann-La Roche Ltd. RITUXAN® SC product monograph. Mississauga, Ontario; March 21, 2018.
104. Sandoz Canada Inc. RIXIMYO® product monograph. Boucherville, Quebec; April 28, 2020.
105. Pfizer Canada-ULC. RUXIENCE® product monograph. Kirkland, Quebec; May 4, 2020.
106. Teva Canada Limited for Celltrion Healthcare Co Ltd. TRUXIMA® product monograph. Toronto, Ontario; July 22, 2019.
107. Celgene Pty Limited. ISTODAX® Australian product information. Mulgrave, Victoria, Australia; February 1, 2022.
108. Gilead Sciences Canada Inc. TRODELVY® product monograph. Mississauga, ON; August 2, 2022.
109. Gilead Medical Information. Gilead Sciences Inc. Personal Communication: Trodelvy® (sacituzumab govitecan) Concentration After Reconstitution. Jan 24, 2022.
110. Recordati Rare Diseases Canada Inc. SYLVANT® product monograph. Toronto, Ontario; July 30, 2024.
111. Recordati Industria Chimica E Farmaceutica (Milan, Italy). Personal Communication: News Release - Recordati completes the acquisition of EUSA Pharma (UK). March 16, 2022.
112. Aadi Bioscience Inc. Pharmacy Manual Protocol PEX-002 (Version 4.0) Expanded Access for an Intermediate-size Population for ABI-009 (Sirolimus Albumin-bound Nanoparticles for Injectable Suspension) in Patients with Perivascular Epithelioid Cell Tumors (PEComa) or Patients with Relevant Genetic Mutations for mTOR Pathway Activation. Pacific Palisades, CA, USA; July 16, 2021.
113. Aadi Bioscience Inc. ABI-009 sirolimus albumin-bound nanoparticle (packaging information - BOX). Pacific Palisades, CA; Feb 1 , 2022.
114. Aadi Bioscience Inc. ABI-009 sirolimus albumin-bound nanoparticle (packaging information - VIAL). Pacific Palisades, CA; Feb 1, 2022.
115. Aadi Bioscience Inc. ABI-009 (*nab*-Sirolimus) Investigator's Brochure - version 10.0. Pacific Palisades, CA, USA; July 27, 2021.
116. Keocyt. Streptozocin Keocyt summary of product characteristics, version 5. Montrouge, France; February, 2016.
117. Keocyt. ZANOSAR® package leaflet. Montrouge, France; 24 February, 2016.
118. Keocyt. ZANOSAR® summary of product characteristics, version 3. Montrouge, France; 31 October, 2017.
119. Keocyt-Riemser Pharma. Marie-Laure Vedel, Sales Order Handling and Hospital Relationship Manager. 16 September, 2021.
120. Amgen Canada Inc. IMDELLTRA® product monograph. Mississauga, Ontario; September 11, 2024.
121. de Lemos, M. BC Cancer Provincial Pharmacy Professional Practice Leader and Drug Information Coordinator. SBAR: Preparing Tarlatamab - BC Cancer Recommendation vs. Product Monograph. BC Cancer - Systemic Therapy Program ; September 12, 2024
122. Medison Pharma Canada Inc.for Immunocore Ireland Limited. KIMMTRAK® product monograph. Toronto, Ontario; June 7, 2022.
123. Pfeiffer, Connie. Head of Medical Affairs Immunocore. Personal Communication. Feb 16, 2022.
124. Janssen Inc. TECVAYLI® product monograph. Toronto, Ontario; July 26, 2023.
125. Janssen Research & Development LLC. Investigational product preparation and Administration instructions for subcutaneous Administration of 10 mg/mL and 90 mg/mL Teclistamab (JNJ-64007957) For Weight-Based Dosing in mcg/kg for Managed Access Programs - Version 6.0 . Beerse, Belgium; June 9, 2023.
126. de Lemos, M. BC Cancer Provincial Pharmacy Professional Practice Leader and Drug Information Coordinator. SBAR: Teclistamab Subcutaneous Injection for Multiple Myeloma at BC Cancer. (draft). BC Cancer - Systemic Therapy Program ; September 1, 2023

127. Pfizer Canada Inc (for Wyeth Canada). TORISEL® product monograph. Kirkland, Quebec; 21 December , 2016.
128. Anna Sivojelezova M.Sc. Medical Information Associate, Wyeth. Personal communication. 6 January, 2010.
129. Bristol-Myers Squibb Canada. VUMON® product monograph. St. Laurent, Quebec; 26 October , 2004.
130. Trissel's®2 IV Compatibility (database on the Internet). Teniposide. Thomson Reuters MICROMEDEX® 2.0; Accessed 27 April, 2011. Available at: http://www.micromedex.com
131. Hikma Canada Limited. Thiotepa for injection product monograph. Mississauga, Ontario; March 14, 2023.
132. AHFS DI® (Adult and Pediatric) (database on the Internet). Thiotepa. UpToDate® Lexidrug®; Accessed October 16, 2024. Updated March 11, 2024. Available at: http://online.lexi.com
133. BC Cancer Miscellaneous Origin Tumour Group. (MOIT) BC Cancer Protocol Summary for Solid Tumours using Intrathecal Methotrexate and/or Thiotepa and/or Cytarabine. Vancouver, British Columbia: BC Cancer; September 1 , 2021.
134. BC Cancer. Systemic Therapy Policy and Procedure III-50: Administration of High Alert Medications by the Intrathecal Route via Lumbar Puncture or Ommaya Reservoir. Vancouver, British Columbia; December 29, 2022.
135. SteriMax Inc. Thiotepa for injection product monograph. Oakville, Ontario; April 5, 2023.
136. Sanofi Genzyme. THYROGEN® product monograph. Mississauga, Ontario; July 29, 2021.
137. BeiGene Ireland Ltd. TEVIMBRA® Summary of product characteristics. Dublin, Ireland; January, 2023.
138. Hoffmann-La Roche Limited. ACTEMRA® product monograph. Mississauga, Ontario; 27 October, 2017.
139. Accord Healthcare Inc. Topotecan hydrochloride for injection product monograph. Kirkland, Quebec; May 9, 2019.
140. BC Children's Hospital (Distribution - Sterile Compounding). Iintrathecal or Intra-OMAYA Compounding Worksheet: Topotecan IT or Intra-Ommaya Syringe. Vancouver, British Columbia; May, 2020.
141. Poplack Potter SL, Berg S, Ingle AM, et al. Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: a Children's Oncology Group trial (P9962). Pediatr Blood Cancer ; 2012;58(3):362–365
142. Pfizer Canada Inc. Topotecan hydrochloride for injection product monograph. Kirkland, Quebec; April 9, 2021.
143. Sandoz Canada Inc. Topotecan injection product monograph. Boucherville, Quebec; March 29, 2019.
144. Hoffmann-La Roche Limited. HERCEPTIN® product monograph. Mississauga, Ontario; May 7, 2020.
145. Celltrion Healthcare Co Ltd (distributed by Teva Canada Limited). HERZUMA® product monograph. Toronto, Ontario; 20 October, 2020.
146. BGP Pharmacy ULC. OGIVRI® product monograph. Etobicoke, Ontario; 3 May, 2019.
147. Pfizer Canada-ULC. TRAZIMERA® product monograph. Kirkland, Quebec; August 15, 2019.
148. AstraZeneca Canada Inc. ENHERTU® product monograph. Mississauga, Ontario; 15 April, 2021.
149. AstraZeneca Canada Inc. Medical Information. 5 October, 2021.
150. Hoffmann-La Roche Limited. KADCYLA® product monograph. Mississauga, Ontario; 11 September, 2013.
151. Hoffmann-La Roche Limited. KADCYLA® product monograph. Mississauga, Ontario; July 3, 2020.
152. AstraZeneca Canada Inc. IMJUDO® product monograph. Mississauga, Ontario; January 26, 2024.
153. Medexus Inc. TRECONDYV® product monograph. Bolton, Ontario; June 25, 2021.
154. Erin Wallace. Ontario Territory Manager, Medexus Pharmaceuticals Inc. Personal Communication - TRECONDYV®. November 2, 2021.
155. Medical Information team. Medexus Pharmaceuticals Inc. Personal Communication - TRECONDYV®. November 1, 2021.
156. medac GmbH. TRECONDI® summary of product characteristics. Wedel, Germany;
157. medac-UK. TREOSULFAN injection® summary of product characteristics. Wedel, Germany; 26 Jan, 2017.
158. medac-UK. TREOSULFAN injection® Details about Handling and Stability. Hamburg, Germany; August, 2008.
159. Henrik Fenger. Management Associate, International Division medac. Personal communication. 03 March, 2010.
160. medac-UK. TREOSULFAN injection® summary of product characteristics. Hamburg, Germany; 24 Jun, 2008.
161. Pfizer Canada-ULC. Vinblastine sulfate injection product monograph. Kirkland, Quebec; April 18, 2019.
162. Lexi-Drugs® (database on the Internet). VinBLAStine. Lexi-Comp Inc.; Accessed 30 January, 2020. Available at: http://online.lexi.com
163. BC Cancer Provincial Systemic Therapy Program. Policy V-40: Dispensing and Labelling of Vinca Alkaloid Preparations. Vancouver, British Columbia: BC Cancer; 1 April , 2015.
164. World Health Organization. Information Exchange System - Vincristine (and other vinca alkaloids) should only be given intravenously via a minibag. Alert No. 115 ed. Geneva, Switzerland: World Health Organization; 18 July , 2007.
165. Teva Canada Limited. Vinblastine sulfate injection product monograph. Toronto, Ontario; 22 October, 2019.
166. Pfizer Canada-ULC. Vincristine sulfate injection product monograph. Kirkland, Québec; July 26, 2021.

167. Teva Canada Limited. Vincristine sulfate injection® product monograph. Scarborough, Ontario; March 27, 2014.
168. Pharmaceutical Partners of Canada. Vinorelbine Injection product monograph. Richmond Hill, Ontario; 15 January , 2008.
169. Generic Medical Partners Inc. Vinorelbine Injection product monograph. Toronto, Ontario; 3 September, 2014.
170. Teva Canada Limited. Vinorelbine tartrate for Injection product monograph. Toronto, Ontario; 20 March, 2014.
171. Innomar Strategies Inc. (for Dr. Reddy's Laboratories Limited). Zoledronic acid for injection concentrate® product monograph. Oakville, Ontario; 11 March, 2015.
172. Marcan Pharmaceuticals Inc. Zoledronic acid concentrate for injection product monograph. Ottawa, Ontario; 5 February, 2018.
173. MDA Inc. Zoledronic acid for injection product monograph. Mississauga, Ontario; 11 August, 2015.
174. Novartis Pharmaceuticals Canada Inc. ZOMETA® product monograph. Dorval, Quebec; 26 July, 2013.
175. Sandoz Canada Inc. Zoledronic Acid - Z® product monograph. Boucherville, Quebec; 02 December, 2016.
176. The United States Pharmacopeia (. General Chapter 797: Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: The United States Pharmacopeial Convention, Inc.; 2004.
177. Kastango ES. The ASHP discussion guide for compounding sterile preparations. Bethesda (MD): American Society of Health-System Pharmacists, Inc.; 2004. p. 5